# RMD Open

Rheumatic & Musculoskeletal Diseases

### **ORIGINAL ARTICLE**

Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations

Christina Duftner,<sup>1</sup> Christian Dejaco,<sup>2,3</sup> Alexandre Sepriano,<sup>4,5</sup> Louise Falzon,<sup>6</sup> Wolfgang Andreas Schmidt,<sup>7</sup> Sofia Ramiro<sup>4</sup>

#### ABSTRACT

**Objectives** To perform a systematic literature review on imaging techniques for diagnosis, outcome prediction and disease monitoring in large vessel vasculitis (LVV) informing the European League Against Rheumatism recommendations for imaging in LVV.

**Methods** Systematic literature review (until 10 March 2017) of diagnostic and prognostic studies enrolling >20 patients and investigating ultrasound, MRI, CT or positron emission tomography (PET) in patients with suspected and/or established primary LVV. Meta-analyses were conducted, whenever possible, obtaining pooled estimates for sensitivity and specificity by fitting random effects models.

Results Forty-three studies were included (39 on giant cell arteritis (GCA), 4 on Takayasu arteritis (TAK)). Ultrasound ('halo' sign) at temporal arteries (8 studies, 605 patients) and MRI of cranial arteries (6 studies, 509 patients) yielded pooled sensitivities of 77% (95% CI 62% to 87%) and 73% (95% CI 57% to 85%), respectively, compared with a clinical diagnosis of GCA. Corresponding specificities were 96% (95% Cl 85% to 99%) and 88% (95% CI 81% to 92%). Two studies (93 patients) investigating PET for GCA diagnosis reported sensitivities of 67%-77% and specificities of 66%-100% as compared with clinical diagnosis or temporal artery biopsy. In TAK, one study each evaluated the role of magnetic resonance angiography and CT angiography for diagnostic purposes revealing both a sensitivity and specificity of 100%. Studies on outcome prediction and monitoring disease activity/damage were limited and mainly descriptive. **Conclusions** Ultrasound and MRI provide a high diagnostic value for cranial GCA. More data on the role of imaging for diagnosis of extracranial large vessel GCA and TAK, as well as for outcome prediction and monitoring in LW are warranted.

#### INTRODUCTION

Large vessel vasculitis (LVV) is the most common form of primary vasculitis comprising (cranial and large vessel (LV)) giant cell arteritis (GCA), Takayasu arteritis

#### Key messages

#### What is already known about this subject?

Imaging modalities including ultrasound (US), MRI, CT and <sup>18</sup>F-FDG positron emission tomography are frequently used for diagnosing large vessel vasculitis (LVV) in clinical practice. However, their diagnostic value is still questioned by several clinicians, especially by those with less experience in imaging.

#### What does this study add?

- US and MRI of the superficial temporal artery reveal a good performance for the diagnosis of cranial giant cell arteritis (GCA) with pooled sensitivities of 77% and 73%, respectively, as well as pooled specificities of 96% and 88%, respectively.
- Studies on the diagnostic accuracy of imaging in extracranial large vessel GCA and Takayasu arteritis are scarce.
- Studies on the role of imaging techniques for outcome prediction and monitoring of disease activity and damage of LVV are limited and mainly non-informative because of heterogeneous study design and of being mostly descriptive, not enabling reaching an inferential conclusion.

#### How might this impact on clinical practice?

- The results of this systematic literature review help clinicians to place the use of imaging in the diagnosis of LW in their daily clinical practice.
- US and MRI of the temporal arteries can be accurately used in the diagnostic work-up of patients with a suspicion of cranial GCA, possibly avoiding the need for more invasive diagnostic techniques, such as a temporal biopsy.

(TAK) and idiopathic aortitis. Prompt diagnosis and treatment of LVV are important to prevent serious ischaemic complications such as visual loss in GCA, vascular

Sepriano A, *et al.* Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and metaanalysis informing the EULAR recommendations. *RMD Open* 2018;**4**:e000612. doi:10.1136/ rmdopen-2017-000612

To cite: Duftner C, Dejaco C,

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (http://dx.doi. org/10.1136/rmdopen-2017-000612).

ChristinD and ChristiaD are first co-authors.

Received 4 November 2017 Accepted 19 December 2017

Check for updates

For numbered affiliations see end of article.

#### **Correspondence to**

Dr Christina Duftner; christina.duftner@gmx.at





stenosis/occlusion in TAK and aneurysm formation in idiopathic aortitis.<sup>1 2</sup> Temporal artery biopsy (TAB) has been the standard test to confirm the diagnosis of GCA<sup>3-5</sup>; although highly specific, biopsy is invasive and lacks sensitivity, with false-negative results in up to 61% of patients compared with a clinical diagnosis of GCA.<sup>6</sup> In addition, extracranial arteries are usually not accessible for histological assessment, and in extracranial LV-GCA, temporal arteries are spared in up to 40% of patients.<sup>78</sup> Consequently, GCA diagnosis often relies on the combination of clinical symptoms, elevated serum inflammatory markers and imaging findings.

The classification criteria for TAK focus on the detection of arterial stenosis and occlusions as detected by conventional angiography.<sup>9</sup> Conventional angiography, however, does not allow the delineation of vessel wall changes and bears the potential risk of complications, such as allergic reactions, haematoma, iatrogenic embolisation and arterial dissection. Therefore, angiography is being increasingly replaced by newer imaging modalities.<sup>2</sup>

Aortitis is common in GCA and TAK but rarely occurs as an isolated (idiopathic) disease.<sup>10</sup> The diagnosis of idiopathic aortitis is frequently based on radiological findings with inflammatory wall changes of the aorta because histological assessment is only possible if aortic aneurysms are operated.<sup>11</sup>

The role of maging modalities including ultrasound (US), MRI, CT and <sup>18</sup>F-FDG positron emission tomography (PET) in LVV has been addressed in several studies over the last years. Imaging modalities, however, are not yet uniformly used for the diagnosis and monitoring of LVV in clinical practice. A European League Against Rheumatism (EULAR) project has therefore been undertaken to develop recommendations for the use of imaging in LVV in clinical practice.<sup>12</sup>

The aim of this systematic literature review (SLR) was to summarise the available evidence on the performance of imaging techniques on diagnosis, outcome prediction and monitoring of disease activity and damage in LVV, as well as technical aspects of imaging modalities in order to inform the EULAR task force developing these new recommendations.<sup>12</sup>

#### METHODS

#### Literature search

In the first meeting of the EULAR task force, four key questions were framed according to the Population, Intervention, Comparator, Outcome (PICO) format.<sup>13</sup> These referred to the role of US, MRI, magnetic resonance angiography (MRA), PET±CT, CT or CT angiography (CTA) in diagnosis, outcome prediction and monitoring of LVV, as well as technical aspects for the different imaging techniques (online supplementary table S1a–d). The population of interest consisted of adult patients (≥18 years) with a suspected (for diagnostic studies and studies on technical aspects) and/or established primary LVV (ie, GCA, TAK and idiopathic aortitis; for

studies on monitoring, prognosis and technical aspects). For diagnostic accuracy of imaging, physician's clinical diagnosis (both at first assessment and also at first and follow-up assessments) and TAB were accepted as reference standards, and sensitivity and specificity of imaging were the outcomes of interest. For prognostic and monitoring studies, presence and absence of baseline imaging abnormalities (or also over the follow-up for monitoring studies) were considered as 'interventions' and 'comparator', respectively; outcomes of interest were those reflecting disease activity or damage. The task force did not specify these outcomes, because it was argued that the literature review would reveal relevant outcome parameters addressed in prospective studies.

Eligible studies were all full research articles of cohort studies with prospective design (excluding research letters, case–control and retrospective studies) involving >20 patients; both cross-sectional and longitudinal studies were included.

# Study selection, data extraction and assessment of risk of bias (RoB)

The SLR was conducted by two reviewers (ChristinD and ChristiaD) under the guidance of the methodologist (SR) and with the help of the statistician (AS), who performed the meta-analyses. The search strategy was developed by an experienced librarian (LF) (online supplementary text S1). MEDLINE (1946), Embase (1974) and the Cochrane Library (1993) databases were searched without language restrictions from their inception dates (noted in parentheses) until 10 March 2017.

The reviewers screened independently all titles and abstracts to identify potentially eligible studies that were then reviewed in full text. Papers fulfilling the inclusion criteria were proceeded to data extraction. Both reviewers independently retrieved data using a predefined data extraction sheet. The following data were extracted for diagnostic studies: studies' main characteristics (year of publication, setting, number of included patients, inclusion criteria, use of glucocorticoids (GC) before performance of imaging), patient characteristics (number (%) of females, patients' age), disease characteristics (number (%) of patients fulfilling clinical criteria for GCA or TAK, number (%) of patients with positive TAB, number (%) of patients with the LV-GCA subset), technical aspects (imaging devices used, elementary lesions and structures investigated, blinding of the index test to reference standard), index test (lesions identified in the index test that are analysed), reference standard, diagnostic performance (raw data to calculate sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR-)) and parameters required for the assessment of the RoB. For prognostic and monitoring studies, the following items were retrieved: study's aim, inclusion criteria, number of patients included, number (%) of patients with follow-up, period of follow-up, investigated structures, signs and time of change, prognostic factors and outcome-as explained above any outcome

reflecting disease activity or damage. For technical aspects, we extracted the study aim, number of included patients, inclusion criteria, number of patients finally diagnosed with GCA or TAK, investigated structures, different technical aspects being compared (intervention and comparator) and outcome (diagnostic performance or disease activity/damage, as appropriate) were detailed.

RoB of the studies was appraised independently by the same two reviewers who conducted the SLR. For studies on diagnostic accuracy, the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool was used comprising four domains: patient selection, index test, reference standard, as well as flow and timing. Each of these domains was evaluated as having a 'low', 'high' or 'unclear' RoB, whereas concerns about applicability were evaluated in the first three domains also as 'low', 'high' or 'unclear'. The Ouality In Prognosis Studies (OUIPS) tool was applied for the assessment of prognostic studies evaluating the following aspects: study participation and attrition, prognostic factor measurement, outcome measurement, study confounding as well as statistical analysis/reporting.14 15 Each QUIPS domain was rated as 'high', 'moderate', 'low' or 'unclear' RoB. For studies on monitoring and technical aspects, no RoB assessment was performed, because identified studies were mainly only descriptive (see below), hence no adequate RoB assessment could be performed. Discrepancies between reviewers regarding study selection, data extraction and RoB assessment were solved by discussion. A third reviewer (WAS) was involved in case no consensus could be achieved (n=2 studies).

#### Data analysis

Meta-analysis for diagnostic accuracy was performed whenever possible, that is, in case enough data stemming from homogeneous studies concerning imaging modality, reference standard (either clinical diagnosis or TAB as reference standards) and outcome assessment was available. For all other diagnostic accuracy studies as well as for prognostic and monitoring studies, individual results (of studies not included in the meta-analysis) are reported.

Pooled sensitivity and specificity were estimated by random-effects bivariate generalised binomial mixed models. This is the recommended analytical method for meta-analysis of diagnostic tests, since it estimates sensitivity and specificity together taking into account their correlation.<sup>16</sup> Parameter estimates from each model were used to derive the LR+ and LR– and 95% CIs. In case of limited data (here:  $\leq 3$  studies), the above-mentioned rule was relaxed, and univariate random-effects models were used by assuming no correlation between sensitivity and specificity.<sup>16</sup>

Sensitivity analyses were performed for diagnostic accuracy studies on US and MRI in GCA evaluating the effect of: (1) the quality of studies (excluding those with high RoB), (2) GC treatment before the index test (including

only those without GC treatment before imaging), (3) the use of imaging devices with high resolution (including only studies that used >12 MHz probes for US or 3T MRI machines), (4) target population (including only studies with a detailed description of what was meant by the 'suspicion' of GCA) and (5) reference standard (including only studies with clinical diagnosis confirmed after follow-up used as reference standard).

All analyses were conducted in Stata V.14. The Cochrane Collaboration's Review Manager Software V.5.3 was used to build forest plots.

#### RESULTS

Out of 8691 articles screened, 43 studies were finally included with some of these addressing more than one index test or key objectives (see flow chart in online supplementary figure S1). For GCA, 27 articles focused on the diagnostic accuracy,<sup>6 17–42</sup>5 studies on outcome prediction,<sup>43–47</sup> 13 on monitoring disease activity<sup>17 20 22 25 28 29 43–45 48–51</sup> and five on technical aspects.<sup>35 37 52–54</sup> For TAK, four studies were included with two studies addressing diagnostic accuracy<sup>55 56</sup> and two studies evaluating the value of imaging for monitoring.<sup>57 58</sup> No study on isolated aortitis was identified.

#### **Diagnostic accuracy studies**

For GCA, most diagnostic accuracy studies focused on the role of US  $(n=17)^{6}$  or MRI (n=8).<sup>33–40</sup> One study addressed the role of PET, <sup>41</sup> and another study examined the role of PET and CTA for GCA diagnosis.<sup>42</sup> In TAK, one study evaluated the role of MRA and another the role of CTA.<sup>55 56</sup>

#### Ultrasound

The main study—and patient—characteristics are summarised in table 1 with additional data and details on the RoB assessment described in online supplementary tables S2 and S6, respectively. Most US studies in GCA tested the 'halo' sign  $(n=16^{6 17-31})$  as a key elementary lesion defining vasculitis. Other US signs addressed (mostly in combination with the 'halo' sign) were stenosis  $(n=13^{6 17 18 \ 20 \ 22-30})$ , occlusion  $(n=9^{6 \ 17 \ 22-26 \ 28 \ 30})$  and the 'compression' sign  $(n=2^{30 \ 32})$ .

Results of the meta-analysis on the diagnostic performance of the different US signs are summarised in table 2, and results of individual studies are shown in figure 1A,B.

Eight studies (n=605, three studies with low RoB)<sup>17 19 20 23 25 28 30 31</sup> investigated the value of the 'halo' sign in comparison with the clinical diagnosis of cranial GCA yielding a pooled sensitivity of 77% (95% CI 62% to 87%) and a specificity of 96% (95% CI 85% to 99%). A similarly good diagnostic performance was obtained when the 'halo' sign was compared with TAB as reference standard (seven studies, n=289, no study with low RoB).<sup>17-21 23 27</sup> Also, the evaluation of the combination of US signs defining vasculitis ('halo', stenosis or occlusion) in comparison with clinical diagnosis (three studies,

	ementary lesions RoB	alo, High enosis/occlusion, lo/stenosis/occlusion	alo High enosis lo/stenosis	High	High			ио глуп ilo/stenosis/occlusion High	المن المن المن المن المن المن المن المن	lo/stenosis/occlusion High Ilo/stenosis/occlusion High colusion Low	Jo/stenosis/occlusion High Io High clusion Low Io/stenosis/occlusion Low Io Low	Io Ingri Io/stenosis/occlusion High iclusion Low Io/stenosis/occlusion Low Io Low Io enosis Mod	lo trugin lo stenosis/occlusion High iclusion Low to Low alo stenosis Mod alo stenosis High	lo stenosis/occlusion High lo stenosis/occlusion Low lo stenosis/occlusion Low lo stenosis Mod lo stenosis Mod	lo trugin lo stenosis/occlusion High lo stenosis/occlusion Low no filo Low no filo high lo stenosis Mod lo stenosis Mod lo high lo high lo high lo high lo high lo stenosis Mod	lo high lo tenosis/occlusion High clusion Low lo stenosis/occlusion Low lo stenosis Mod lo tenosis Mod lo tenosis Mod lo tenosis Mod
	nvestigated tructures Elem	A halo, steno halo/s	A halo steno halo/s	A halo	A halo	A halo		A, occipital halo/s	A, occipital halo/s A halo	A, occipital halo/s A halo occlu A halo/s	A, occipital halo/s A halo A halo/s A halo/s steno	<ul> <li>A, occipital halo/s</li> <li>A halo/s</li> <li>A halo/s</li> <li>A halo/s</li> <li>A carotid, halo/s</li> <li>eriorbital</li> </ul>	A, occipital halo/s A halo/s A halo/s A halo/s A, carotid, halo/ eriorbital A halo/	A, occipital halo/s A halo/s A halo/s A halo/s A carotid, halo/s eriorbital A, carotid, halo/s eriorbital, halo/s eriorbital, halo/s manoral, opliteal	A, occipital halo/s A halo/s A halo/s A halo/s artebral, halo/s eriorbital A halo/s artebral, halo/s artebral, halo/s artebral, halo/s artebral, halo/s artebral, halo/s artebral, halo/s artebral, halo/s artebral, halo/s balo/s A halo	A, occipital halo/s A halo/s A halo/s A halo/s A, carotid, halo/s eriorbital A, carotid, halo/s eriorbital A halo/s
	In n LV-GCA st	NR TA	NR TA	NR TA	NR TA	NR TA		NR TA	NR RN TA	NR NR NR NR NR NR NR	AN AN AN AN AN AT AT AT AT AT	AN A	AN A	AR A	AR A	AN A
	n TAB+ (%)	21 (78)	7 (100)	9 (64)	15 (75)	7 (100)	100/ 00	33 (bJ)	33 (83) 33 (77)	33 (83) 33 (77) 22 (100)	33 (77) 33 (77) 22 (100) 18 (82)	33 (77) 33 (77) 22 (100) 18 (82) 89 (75)	33 (77) 33 (77) 22 (100) 18 (82) 89 (75) 5 (100)	33 (77) 22 (100) 18 (82) 5 (100) 35 (95)	33 (77) 33 (77) 22 (100) 18 (82) 89 (75) 5 (100) 35 (95) 15 (94)	33 (77) 33 (77) 22 (100) 18 (82) 89 (75) 5 (100) 35 (95) 15 (94) 15 (94) 20 (53)
	Final diagn BCA (%)	30 (27)	7 (22)	14 (20)	20 (23)	7 (27)	40 (RO)	(>>) ot	43 (52)	43 (52) 22 (32)	43 (52) 22 (32) 22 (40)	43 (52) 22 (32) 22 (40) 32 (73)		43 (52) 22 (32) 22 (40) 5 (28) 38 (53)	43 (52) 22 (40) 22 (40) 32 (73) 38 (53) 16 (50)	43 (52) 22 (40) 22 (40) 32 (73) 38 (53) 43 (50) 43 (54)
l in GCA	r erence standard	R criteria or 3	~	nical diagn 6m or 3	R criteria or 3	~			a critera or R crit or	R crit or	R crit or 8 crit or 8 1 cal diagn 3 m or 1 cal diagn 3 m or	R crit or R crit or a ical diagn 3m or ical diagn ical diagn rospectively firmed)	R crit or R crit or ical diagn 3m or ical diagn rospectively firmed)	R crit or B crit or a diagn 3m or ical diagn ical diagn rospectively firmed) B Criteria	R crit or B crit or a lical diagn 3m or ical diagn rospectively fiftmed) B R criteria R criteria B rotan 3m or	R crit or B crit or B crit or ical diagn 3m or rospectively fiftmed) B criteria R criteria R criteria
es on ultrasound	on criteria Ref	cted ACI	cted GCA TAE	sted GCA Clir. TAE	sted ACI MR TAE	sted GCA TAE	sted GCA ACI	TAE	TAE ACI TAE	TAB ACF TAE cted GCA TAE	TAB AGF ACF ACF ACF ACF ACF ACF ACF ACF ACF AC	TAE Sted GCA TAE 50mm/h, Clin 50mm/h, Clin 30mm/h, Clin attion, Clin attion, Clin MrR, TA attion, Clin MrR, TAE PMR, TAE Clin Clin Clin Clin Clin Clin Clin Clin	TAE Sted GCA TAE Somm/h, Clin she, jaw TAE ation, Clin she, jaw TAE ation, Clin bhent Clin teted CA TAE US* (retu	TAB Sted GCA 50mm/h, TAE atton, he, jaw AMR, TA atton, Clin AMR, TA atton, Clin AMR, TAE atton, Clin TAE atton, TAE atton Sted CCA Clin Soft Cted GCA Clin Cted GCA Clin Cted GCA Clin Soft Cted CCA Clin Clin Clin Clin Clin Clin Clin Clin	TAB Sted GCA Somm/h, TAE atton, he, jaw ACF atton, Clin ARF, TA atton, Clin atton, Clin AR, TA best, visual cent Somm/h, Clir fet LV- Somm/h, Clir for siaw draft Somm/h, Clir for siaw overs) Somm/h, Clir for siaw atton, Clir for siaw atton, Clir for siaw atton, Clir for siaw for the for the fo	TAB Sted GCA Sted GCA atton, MR, TA atton, MR, TA atton, MR, TA atton, MR, TA Somm/h, Overs) Somm/h, Overs) Somm/h, Clin TAE Clin Clin Clin Clin Clin Clin Clin Clin
agnostic studie	nale (%) Inclusic	Suspec GCA+P	36) Suspec	Suspec	34) Suspec GCA+PI	Suspec	76) Suspec:		59) NR	() Suspec	<ul> <li>(9) NR</li> <li>(1) Suspec</li> <li>(1) Suspec</li> <li>(1) ESR &gt;5</li> <li>(5) ESR &gt;5</li> <li>(5) Fever, P</li> <li>(1) fever, P</li> <li>(1) tendern</li> <li>(1) impair</li> </ul>	<ul> <li>(9) NR</li> <li>(1) Suspection</li> <li>(5) ESR &gt;5i headach</li> <li>(1) Fever, P</li> <li>(1) tendern</li> <li>(1) tendern</li> <li>(1) tendern</li> <li>(2) Suspection</li> <li>(3) GCA+U</li> </ul>	<ul> <li>(9) NR</li> <li>(1) Suspec</li> <li>(1) Suspec</li> <li>(5) ESR &gt;5/</li> <li>(5) ESR &gt;5/</li> <li>(1) Suspec</li> <li>(1) Suspec</li> <li>(2A+U</li> </ul>	<ul> <li>(9) NR</li> <li>(1) Suspec</li> <li>(1) Suspec</li> <li>(audice fever, Pl</li> <li>headad</li> <li>claudice fever, Pl</li> <li>tender, Pl</li></ul>	<ul> <li>(9) NR</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(2) Suspect</li> <li>(3) Suspect</li> <li>(3) Suspect</li> <li>(4) Fandern</li> <li>(4) Fandern</li> <li>(4) Fandern</li> <li>(4) Fandern</li> <li>(4) Fandern</li> <li>(4) Fandern</li> </ul>	<ul> <li>(9) NR</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(2) Suspect</li> <li>(3) Suspect</li> <li>(3) Suspect</li> <li>(4) Suspect</li> <li>(4) Suspect</li> <li>(5) Suspect</li> <li>(6) ESR &gt;5</li> <li>(5) BSR &gt;5</li> <li>(6) Suspect</li> <li>(6) Suspect</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(1) Suspect</li> <li>(2) Suspect</li> <li>(3) Suspect</li> <li>(3) Suspect</li> <li>(4) Suspect</li> <li>(4) Suspect</li> <li>(5) Suspect</li> <li>(5) Suspect</li> <li>(5) Suspect</li> <li>(5) Suspect</li> <li>(6) Suspect</li> <li>(6) Suspect</li> </ul>
ICS OT OIS	n Fen	2 NR	2 21 (6	9 NR	6 55 (f	6 NR	7 51 (7		3 49 (F	3 49 (5 8 48 (7	5 30 (f	2 NR	8 12 23 49 (1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 49 (5 1 4 (6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2 2 49 (J , 10) 2 49 49 (J , 10) 4 4 4 (f , 10) 4 4 4 (f , 10) 4 4 6 (f , 10) 4 6 (f , 10)	10     <
Iracteristic	Ę	112	32	69	86	26	22	ar 0/	a 83	83 83 83	22 83 33 55 24 83 55	ar ov 68 55 55 132	<sup>26</sup> 132 <sup>26</sup> 132 <sup>7</sup> 18	<sup>26</sup> 132 <sup>26</sup> 132 7 72	<sup>26</sup> 132 <sup>26</sup> 132 7 18 72 32 32	<sup>26</sup> 132 <sup>26</sup> 132 7 18 32 80 80
	CI Apr	hmidt <i>et al</i> <sup>17</sup>	Sar et al <sup>18</sup>	sher et al <sup>19</sup>	lvarani <i>et al<sup>20</sup></i>	ırgatroyd <i>et al</i> ²¹		adenhauer and Web	tdenhauer and Web <sup>6</sup> inhard et a <sup>23</sup>	tdenhauer and Webu inhard et al <sup>23</sup> mera-Villegas et al <sup>2</sup>	tdenhauer and Webo inhard <i>et al<sup>a</sup>s</i> mera-Villegas <i>et al</i> <sup>2</sup> rahaliou e <i>t al<sup>a</sup></i> s	idenhauer and Webo inhard <i>et al<sup>23</sup></i> mera-Villegas <i>et al</i> <sup>2</sup> rahaliou <i>et al</i> <sup>25</sup> rahaliou <i>et al</i> <sup>25</sup> adenhauer and Behr	idenhauer and Webe inhard et al² mera-Villegas et al² rahaliou et al² adenhauer and Behr ragozá-Garciá et al²	idenhauer and Webe inhard <i>et al</i> <sup>a</sup> mera-Villegas <i>et al</i> <sup>2</sup> rahaliou <i>et al</i> <sup>a</sup> adenhauer and Behr ragozá-Garciá <i>et al</i> <sup>a</sup> chwanden <i>et al</i> <sup>2</sup>	tdenhauer and Webo Inhard <i>et al</i> <sup>23</sup> mera-Villegas <i>et al</i> <sup>2</sup> rahaliou <i>et al</i> <sup>25</sup> ragozá-Garciá <i>et al</i> <sup>2</sup> chwanden <i>et al</i> <sup>29</sup> bib <i>et al</i> <sup>83</sup>	idenhauer and Web inhard et al <sup>23</sup> mera-Villegas et al <sup>2</sup> rahaliou et al <sup>25</sup> ragozá-Garciá et al <sup>2</sup> chwanden et al <sup>29</sup> bib et al <sup>8</sup> chwanden et al <sup>30</sup>

6

Table 1 Continued										
Study ID	Ē	n Female (%)	Inclusion criteria	Reference standard	n Final diagn GCA (%)	n TAB+ (%)	n LV-GCA	Investigated structures	Elementary lesions	RoB
Diamantopoulos <i>et al<sup>31</sup></i>	88	54 (61)	CRP >5 mg/ dL, headache, jaw claudication, fever, PMR, TA tenderness, visual impairment	Clinical diagn 6m or TAB	46 (52)	26 (67)	17	TA, carotids, axillary	halo	Low
Aschwanden <i>et al<sup>32</sup></i>	60	40 (67)	Suspected GCA	ACR criteria	24 (40)	13 (72)	NR	ТА	ompression	Low
Luqmani et a/ <sup>6</sup>	381	273 (72)	Suspected GCA	Clinical diagn 6m or TAB	257 (67)	101 (39)	Yes (n NR)	TA, axillary	halo/stenosis/occlusion	Mod
*Suspected GCA+US, only ACR, American College of moderate: m, months; n, nu number of GCA patients wi	/ patients Rheumat umber of ith large v	with suspected tology; APR, acu finally included vessel involvem	l disease and an availa ute phase reactants; C patients in analysis; n ent: n TAB+. number o	ble ultrasound examinat RP, C-reactive protein; c female, number of fems f positive temboral arter	ion were included liagn, diagnosis; E tles; n final diagn ( v biopsv results ir	SR, erythrocyte s SCA, number of p i finally diagnosed	sedimentation rat patients finally dia d GCA patients: F	e; GCA, giant cel agnosed with GC MR. polvmvaldi	l arteritis; LV, large vessel; moo A; NR, not reported; n LV-GCA t rheumatica: PET+, imacind s	d, i ans

suggestive for LV-GCA in positron emission tomography; RoB, overall appraisal of risk of bias and concerns about applicability (arbitrarily defined) (high, in the case of concern on 25/10 risk of bias items

concern on 4/10

in case of

or concern on 3/3 applicability items out of the QUADAS-2 tool; moderate,

concern on  $\leq 3/3$  risk of bias items and no concern about applicability):

. ک

temporal artery/arteries; TAB+, patients with a positive histology suggesting vasculitis.

RoB items and/or concern on ≥1/3 applicability items out of the QUADAS-2 tool; low, in case of

n=560, no study with low RoB)<sup>6 17 22</sup> or TAB (five studies, n=611, one study with low RoB)<sup>6 17 22–24</sup> resulted in a similar diagnostic performance as the 'halo' sign alone. Sensitivity analyses for the diagnostic performance of the 'halo' sign (compared with clinical diagnosis of cranial GCA) as detailed above, revealed higher pooled sensitivities (86%–89%) than the main analysis and comparable or slightly lower specificities. The only exception was the analysis including only studies without GC treatment before the index test, which had a slightly lower sensitivity of 73% (table 3).

Two studies (n=140, both with low RoB),<sup>30 32</sup> conducted by the same research group, investigated the 'compression' sign. The authors reported sensitivities of 77%–79% and a specificity of 100% of this sign compared with the clinical diagnosis of cranial GCA.

In three US studies<sup>6</sup><sup>29 31</sup> (n=541, one study with low RoB), extracranial arteries were examined. Only one of these addressed the effect of the examination of temporal plus axillary arteries on the diagnostic performance as compared with the assessment of temporal arteries alone. This study revealed an incremental change of sensitivity of 2% by the former compared with the latter approach.<sup>31</sup> Although 22 arteries were evaluated in the study by Aschwanden *et al*<sup>29</sup> a low sensitivity of 55% was observed for US ('halo' and stenosis) to detect vasculitis. No separate results for the diagnostic performance of US in patients with cranial and extracranial LV involvement were provided in that study.<sup>29</sup>

No study on US in TAK was identified.

#### Magnetic resonance imaging

All MRI studies addressed vessel wall thickening and contrast enhancement as signs of vasculitis in the superficial temporal and occipital arteries. Study characteristics are detailed in table 4, individual sensitivity and specificity data are reported in online supplementary table S3 and figure 1A,B and details of the RoB assessment are shown in online supplementary table S6.

Six MRI studies were included in the meta-analysis using clinical diagnosis<sup>33–35</sup> <sup>38–40</sup> (n=509, one with low RoB) and/or TAB $^{33-35\ 37\ 38\ 40}$  (n=443, one with low RoB) as the reference standard (table 2). A pooled sensitivity of 73% (95% CI 57 to 85) and specificity of 88% (95% CI 81 to 92) was found comparing MRI with the clinical diagnosis of cranial GCA. When TAB was used as the reference standard, MRI yielded a sensitivity of 93% (95% CI 89 to 96) and a specificity of 81% (95% CI 73) to 87). Sensitivity analyses, as detailed in table 3, underlined the robustness of the main analysis. Of note, in all included MRI studies, patients were on treatment with GCs when the MRI was conducted. One study examined the role of the deep temporal arteries and the involvement of the temporal muscle for the diagnosis of GCA revealing a sensitivity of 42% and a specificity of 90% (online supplementary table S3).<sup>36</sup> This study was not included in the meta-analysis because the structures investigated were different from those of other studies.

Table 2Results of the meta-analysreference standard for giant cell arte	sis (pooled estimates) for aritis (GCA)	ultrasound and MRI signs of vasculitis	s in comparison with	clinical diagnosis	or temporal arter	y biopsy as
Index test	Reference standard	Number of patients (number of studies)	LR+ (95% CI)	LR- (95 % CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ultrasound						
'Halo' sign*	Clinical diagnosis	605 (eight studies) <sup>17 19 20 23 25 28 30 31</sup>	19 (4.8 to 75.5)	0.2 (0.1 to 0.4)	77 (62 to 87)	96 (85 to 99)
'Halo' sign±stenosis±occlusion†	Clinical diagnosis	560 (three studies) <sup>6 17 22</sup>	6.9 (3 to 16.1)	0.3 (0.1 to 0.6)	78 (57 to 90)	89 (78 to 95)
'Compression' sign‡	Clinical diagnosis	140 (two studies) <sup>30 32</sup>	++	++	++	++
'Halo' sign*	TAB	289 (seven studies) <sup>17–21</sup> 23 27	4.3 (2.4 to 7.8)	0.4 (0.2 to 0.6)	70 (56 to 81)	84 (73 to 91)
'Halo' sign±stenosis†	TAB	50 (two studies) <sup>18 27</sup>	8.4 (2.4 to 30.1)	0.3 (0 to 1.6)	77 (23 to 97)	91 (75 to 97)
'Halo' sign±stenosis±occlusion*	TAB	611 (five studies) <sup>6 17 22-24</sup>	8.3 (2.5 to 27.4)	0.2 (0.1 to 0.7)	78 (48 to 93)	91 (70 to 98)
MRI						
MRI*	Clinical diagnosis	509 (six studies) <sup>33-35 38-40</sup>	5.9 (3.4 to 10.3)	0.3 (0.2 to 0.5)	73 (57 to 85)	88 (81 to 92)
MRI*	TAB	443 (six studies) <sup>33-35 37 38 40</sup>	5 (3.2 to 7.8)	0.1 (0.1 to 0.1)	93 (89 to 96)	81 (73 to 87)
*Bivariate random-effects binomial gener	ralised mixed model.					

tUnivariate random-effects models.

tModel fails to converge with both analytical methods.

halo' sign ±stenosis, combination of 'halo' sign±stenosis as ultrasound signs suggestive for vasculitis; 'halo' sign±stenosis±occlusion, combination of halo±stenosis±occlusion as ultrasound

signs suggestive for vasculitis; MRI, magnetic resonance imaging; wall thickening+contrast enhancement as MRI signs suggestive for vasculitis.

ACR, American College of Rheumatology; Cl, confidence interval; clinical diagnosis, final diagnosis made according to the ACR criteria or physician diagnosis; LR, likelihood ratio; TAB, temporal artery biopsy.

#### US ("halo" sig

Study Schmidt WA 1997									
Schmidt WA 1997		TP	FP	FN	TN	Sensitivity (95% C	D Specificity (95% CD	Sensitivity (95% CI)	Specificity (95% CI)
and the second second second		22	0	8	82	0 73 10 54 0 00	1 00 0 96 1 001		
Nesher G 2002		12	12	2	43	0.8610.57 0.00	0.78 (0.65, 0.00)		
Salvarani C 2002		7	14	13	52	0.35 (0.57, 0.90	0.70 [0.00, 0.80]		
Bainbard M 2004		26	0	17	40	0.60 (0.44, 0.74			_
Karabaliou M 2006		18	3	4	30	0.82 10 60 0.94	0.91 (0.76 0.00)		
Habib HM, 2012		13	2	3	14	0.81 10.54 0.94	0.88 (0.62, 0.98)		
Aschwanden M. 2013		34	õ	9	37	0.79 10.64 0.90	1.00 (0.91, 1.00)		_
Diamantopoulos A. 201	4	44	2	2	40	0.96 [0.85. 0.99	0.95 [0.84, 0.99]		· · · · · · · · · · · · · · · · · · ·
								0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1
JS ("halo" sign	± Si	ten	os	is ±	00	cclusion)			
Study	TP	FF	2	FN	TN	Sensitivity (95% C	) Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Schmidt WA. 1997	28	8 8	6	2	76	0.93 [0.78, 0.99	0.93 [0.85, 0.97]		-
Pfadenhauer K. 2003	33	3 3	3	7	24	0.82 [0.67, 0.93	0.89 [0.71, 0.98]		
Luqmani R. 2016	139	23	3 11	18 1	01	0.54 [0.48, 0.60	0.81 [0.73, 0.88]		H-1-1-T
								0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8
JS ("compression	on"	si	gn)	)	_				
Study	TP	FF	FI	N TI	S	ensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Aschwanden M. 2013	34	0	1 1	9 3	0	0.79 [0.64, 0.90]	1.00 [0.91, 1.00]		
Ascriwanden M. 2015	19	. (		5 31	0	0.79 [0.58, 0.93]	1.00 [0.90, 1.00]	0 0 0 0 0 0 0 0 0	0 0 2 0 4 0 6 0 0
								0 0.2 0.4 0.0 0.8 1	0 0.2 0.4 0.0 0.8 1
VIRI									
Study	TP	FP	EN	TN	Se	ensitivity (95% Ch	Specificity (95% Ch	Sensitivity (95% Ch	Specificity (95% Ch
Blev TA 2005		1	4	11		0 89 10 52 1 001	0.9210.62 1.001		
Bley TA 2005	25	1	6	11		0.83 [0.52, 1.00]	0.92 [0.02, 1.00]		-
Geiger 1 2007	19		0	11		0.68 [0.48 0.93]	0.73 [0.64, 1.00]	_	
Klink T 2014	83	10	19	73		0.81 [0.72 0.84]	0.88 [0.79 0.92]		
Siemonsen S. 2015	16	1	4	4		0.80 [0.56 0.94]	0.80 [0.28, 0.94]		
Rheaume M. 2017	54	6	83	28		0.39 [0.31, 0.48]	0.82 [0.65, 0.93]		
		5	03	*0		0.00 [0.01, 0.40]	0.02 [0.00, 0.00]	0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1
is cholo" cian)									
o ( naio sign)		TC		-	-	Constitute (Const	D. Constitute (OCt. Con	Canalitaita (OFC Ca	Canadificity (OCT) on
Study		TP	FP	FN	TN	Sensitivity (95% 0	I) Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Study Schmidt WA, 1997		TP 16	FP 2	FN 5	TN 24	Sensitivity (95% 0	Specificity (95% Cl)           2]         0.92 [0.75, 0.99]	Sensitivity (95% CI)	Specificity (95% CI)
Study Schmidt WA. 1997 Lesar CJ. 2002		TP 16 6	FP 2 2	FN 5	TN 24 23	Sensitivity (95% 0 0.76 [0.53, 0.9 0.86 [0.42, 1.0	Specificity (95% CI)           2]         0.92 [0.75, 0.99]           0]         0.92 [0.74, 0.99]	Sensitivity (95% CI)	Specificity (95% CI)
Study Schmidt WA. 1997 Lesar CJ. 2002 Nesher G. 2002		TP 16 6 7	FP 2 2 9	FN 5 1 2	TN 24 23 14	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.40, 0.9	Specificity (95% CI)           2]         0.92 [0.75, 0.99]           0]         0.92 [0.74, 0.99]           7]         0.61 [0.39, 0.80]	Sensitivity (95% CI)	Specificity (95% CI)
Study Schmidt WA. 1997 Lesar CJ. 2002 Nesher G. 2002 Salvarani C. 2002	50	TP 16 6 7	FP 2 2 9 15	FN 5 1 2 9	TN 24 23 14 56	Sensitivity (95% 0 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.40, 0.9 0.40 [0.16, 0.6	Specificity (95% Cl)           2]         0.92 [0.75, 0.99]           0]         0.92 [0.74, 0.99]           7]         0.61 [0.39, 0.80]           8]         0.79 [0.68, 0.88]	Sensitivity (95% CI)	Specificity (95% CI
Study Schmidt WA, 1997 Lesar CJ. 2002 Nesher G. 2002 Salvarani C. 2002 Murgatroyd H. 2003	-	TP 16 6 7 6	FP 2 2 9 15 6	FN 5 1 2 9 1	TN 24 23 14 56 13	Sensitivity (95% 0 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.40, 0.9 0.40 [0.16, 0.6 0.86 [0.42, 1.0	Specificity (95% Cl)           21         0.92 [0.75, 0.99]           0.92 [0.74, 0.99]           71         0.61 [0.39, 0.89]           81         0.79 [0.68, 0.88]           01         0.68 [0.43, 0.87]	Sensitivity (95% CI)	Specificity (95% Cl)
Study Schmidt WA. 1997 Lesar CJ. 2002 Nesher G. 2002 Salvarani C. 2002 Murgatroyd H. 2003 Reinhard M. 2004		TP 16 6 7 6 22	FP 2 2 9 15 6 1	FN 5 1 2 9 1	TN 24 23 14 56 13 14	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.40, 0.9 0.40 [0.16, 0.6 0.86 [0.42, 1.0 0.67 [0.48, 0.8	Specificity (95% CI)           21         0.92 (0.75, 0.99)           00         0.92 (0.74, 0.99)           71         0.61 (0.39, 0.80)           81         0.79 (0.68, 0.88)           91         0.68 (0.43, 0.87)           92         0.93 (0.68, 1.00)	Sensitivity (95% CI)	Specificity (95% CI)
Study Schmidt WA. 1997 Lesar CJ. 2002 Nesher G. 2002 Salvarani C. 2002 Murgatroyd H. 2003 Reinhard M. 2004 Zaragoza Garcia JM. 201	07	TP 16 6 7 6 22 4	FP 2 9 15 6 1	FN 5 1 2 9 1 11 1	TN 24 23 14 56 13 14 12	Sensitivity (95% 0 0.76 (0.53, 0.9 0.86 (0.42, 1.0 0.78 (0.40, 0.9 0.40 (0.16, 0.6 0.86 (0.42, 1.0 0.67 (0.48, 0.8 0.80 (0.28, 0.9	Specificity (95% CI)           0.92 [0.75, 0.99]           0.92 [0.74, 0.99]           0.61 [0.39, 0.80]           0.79 [0.68, 0.88]           0.68 [0.43, 0.87]           0.93 [0.68, 1.00]           9]         0.92 [0.64, 1.00]	Sensitivity (95% Cl)	Specificity (95% CI)
Study Study Schmidt WA. 1997 Lesar CJ. 2002 Nesher G. 2002 Salvarani C. 2002 Murgatroyd H. 2003 Reinhard M. 2004 Zaragoza Garcia JM. 201 JS ("halo" sign ::	07 ± <b>S</b> 1	TP 16 6 7 6 22 4	FP 2 9 15 6 1 1	FN 5 1 2 9 1 11 1 1 1 5	TN 24 23 14 56 13 14 12	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.40, 0.9 0.40 [0.16, 0.6 0.86 [0.42, 1.0 0.67 [0.48, 0.8 0.80 [0.28, 0.9	Specificity (95% CI)           21         0.92 [0.75, 0.99]           0.92 [0.74, 0.99]         0.61 [0.33, 0.80]           0.79 [0.68 [0.38, 0.88]         0.79 [0.68 [0.43, 0.87]           0         0.66 [0.43, 0.87]           0         0.68 [0.43, 0.87]           0         0.52 [0.68, 1.00]	Sensitivity (95% Cl)	Specificity (95% CI)
Study Schmidt WA 1997 Lesar CJ. 2002 Nesher G. 2002 Salvarani C. 2002 Reinhard M. 2004 Zaragoza Garcia JM. 201 JS ("halo" sign : Study	07 ± <b>S</b> 1	TP 16 6 7 6 22 4 4 ten	FP 2 9 15 6 1 1 1 8 0 5 FP	FN 5 1 2 9 1 11 1 1 5 5 7 8 5 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7	TN 24 23 14 56 13 14 12 TN	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.40, 0.9 0.40 [0.16, 0.6 0.86 [0.42, 1.0 0.67 [0.48, 0.8 0.80 [0.28, 0.9 Sensitivity (95% C	1)         Specificity (95% CI)           21         0.92 [0.75, 0.99]           0         9.20 [0.74, 0.99]           0         0.61 [0.39, 0.60]           81         0.79 [0.68, 0.83]           0         0.68 [0.43, 0.87]           21         0.93 [0.68, 1.00]           91         0.52 [0.64, 1.00]	Sensitivity (95% Cl)	Specificity (95% CI)
Study Schmidt WA. 1997 Lesar CJ. 2002 Nesher G. 2002 Salvarani C. 2002 Salvarani C. 2002 Reinhard M. 2004 Zaragoza Garcia JM. 201 Zaragoza Garcia JM. 201 JS ("halo" sign : Study Lesar CJ. 2002	07 ± \$1	TP 16 6 6 22 4 ten 7	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 5 5	TN 24 23 14 56 13 14 12 TN 20	Sensitivity (95% 0 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.40, 0.9 0.40 [0.16, 0.6 0.86 [0.42, 1.0 0.87 [0.48, 0.8 0.80 [0.28, 0.9 Sensitivity (95% 0 0.58 [0.28, 0.8	I) Specificity (95% CI)     0.92 (0.75, 0.99)     0.92 (0.74, 0.99)     0.92 (0.74, 0.99)     0.61 (0.33, 0.80)     0.68 (0.43, 0.87)     0.68 (0.43, 0.87)     0.92 (0.64, 1.00)     0.92 (0.64, 1.00)     Specificity (95% CI)     Specificity (95% CI)     100 (0.83, 1.00)	Sensitivity (95% Cl)	Specificity (95% CI)
Sudy Schmidt WA. 1997 Lesar CJ. 2002 Nesher G. 2002 Salvarani C. 2002 Reinhard M. 2004 Zaragoza Garcia JM. 201 JS ("halo" sign : Study Lesar CJ. 2002 Zaragoza Garcia JM. 201	)7 ± <b>SI</b>	TP 16 6 22 4 ten 7 5	FP 2 9 15 6 1 1 1 1 0 0 5 FP 0 3	FN 5 1 2 9 1 11 1 1 <b>is)</b> FN 5 0	TN 24 23 14 56 13 14 12 TN 20 10	Sensitivity (95% C 0.76 (0.53, 0.9 0.86 (0.42, 1.0 0.78 (0.40, 0.9 0.40 (0.16, 0.6 0.86 (0.42, 1.0 0.67 (0.48, 0.8 0.80 (0.28, 0.9 Sensitivity (95% C 0.58 (0.28, 0.8 1.00 (0.48, 1.0	1)         Specificity (95% CI           21         0.92 [0.75, 0.99]           0.92 [0.75, 0.99]         0.92 [0.74, 0.99]           10         0.61 [0.39, 0.60]           0.61 [0.39, 0.60]         0.79 [0.68, 0.86]           0.63 [0.43, 0.87]         0.33 [0.68, 1.00]           9]         0.92 [0.64, 1.00]           9]         0.92 [0.64, 1.00]           9]         0.92 [0.64, 1.00]           9]         0.92 [0.64, 1.00]           9]         0.92 [0.64, 1.00]           9]         0.92 [0.64, 1.00]           9]         0.92 [0.64, 1.00]           9]         0.92 [0.64, 1.00]	Sensitivity (95% CI)	Specificity (95% CI)
Sudy Schnidt Study Schnidt WA. 1997 Lesar CJ. 2002 Saharand C. 2002 Saharand C. 2002 Reinhard M. 2004 Zaragoza Garcia J.M. 201 Zaragoza Garcia J.M. 201 Lesar CJ. 2002 Zaragoza Garcia J.M. 201 K. ("halo" sign : Study C. ("halo" sign :	)7 ± SI	TP 16 6 222 4 ten 7 5	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 11 1 1 FN 5 0 FN 5 0	TN 24 23 14 56 13 14 12 10 TN 20 10	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.40, 0.9 0.40 [0.16, 0.6 0.86 [0.42, 1.0 0.67 [0.48, 0.8 0.80 [0.28, 0.9 0.80 [0.28, 0.9 1.00 [0.48, 1.0 cclusion]	1)         Specificity (95% CI)           2         0.22 (0.75, 0.99)           0.92 (0.75, 0.99)         0.92 (0.74, 0.99)           7         0.61 (0.39, 0.60)           0.70 (0.68, 0.88)         0.66 (0.43, 0.67)           0.92 (0.64, 1.00)         99         0.92 (0.64, 1.00)           11         Specificity (95% CI)         1.00 (0.83, 1.00)           0.77 (0.46, 0.95)         0.77 (0.46, 0.95)	Sensitivity (95% CI)	Specificity (95% C)
Sudy Schmidt Sign) Schmidt WA. 1997 Lesar CJ. 2002 Nesher G. 2002 Sahvaran C. 2002 Murgatory H. 2003 Renhard M. 2004 Zaragoza García JM. 201 ZS. dy C. 2002 Lesar CJ. 2002 Zaragoza García JM. 201 JES ("halo" sign : Study Lesar CJ. 2002 Zaragoza García JM. 201 JES ("halo" sign : Study	)7 ± SI )7 ± SI	TP 16 6 7 6 6 22 4 ten TP 7 5 ten TP	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 9 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 14 12 12 TN 20 10	Sensitivity (95% c 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 1.0 0.78 [0.42, 0.0 0.40 [0.16, 0.6 0.66 [0.42, 1.0 0.66 [0.42, 0.0 0.60 [0.28, 0.9 0.80 [0.28, 0.8 1.00 [0.48, 1.0 0.58 [0.28, 0.8 1.00 [0.48, 1.0 0.58 [0.28, 0.8 1.00 [0.48, 1.0 0.58 [0.28, 0.8 1.00 [0.48, 1.0 0.58 [0.28, 0.8] 1.00 [0.48, 1.0 0.58 [0.28, 0.8]	<ol> <li>Specificity (95% CI)</li> <li>0.92 (0.75, 0.96)</li> <li>0.92 (0.76, 0.97)</li> <li>0.92 (0.76, 0.98)</li> <li>0.70 (0.66, 0.88)</li> <li>0.70 (0.66, 0.88)</li> <li>0.92 (0.66, 1.00)</li> <li>0.92 (0.66, 0.88)</li> <li>0.92 (0.66, 0.8</li></ol>	Sensitivity (95% CI)	Specificity (95% CI)
Study Schmidt WX.1997 Lear CJ. 2002 Nesher G. 2002 Salvaran C. 2002 Margatory H. 2003 Reinhard M. 2004 Zangoza Garcia JM. 201 Zangoza Garcia JM. 201 JS. ("halo" sign : Study Lear CJ. 2002 Zangoza Garcia JM. 201 JS. ("halo" sign : Study Chandar M. 1007	07 ± s1 07 ± s1	TP 16 6 7 6 22 4 ten TP 7 5 ten TP 20	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 9 1 11 1 1 1 1 1 1 1 1 1 1 1 1 5 0 1 5 5 0 1 5 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 14 12 10 10 10 10 00 TN 20 10	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 1.0 0.78 [0.42, 0.0 0.40 [0.16, 0.6 0.66 [0.42, 1.0 0.67 [0.48, 0.9 0.67 [0.48, 0.9 0.68 [0.28, 0.9 1.00 [0.48, 1.0 20 [1.00 [0.48, 1.0] 20 [1.00 [0.48, 1.0] 20 [1.00 [1	3)         Specificity (95% CI)           21         0.92 (0.75, 0.99)           0.92 (0.76, 0.99)         0.92 (0.76, 0.99)           0.92 (0.76, 0.98)         0.79 (0.66, 0.88)           0.79 (0.66, 0.88)         0.79 (0.66, 0.88)           0.92 (0.64, 1.09)         0.92 (0.64, 1.00)           1.00 (0.93, 1.00)         0.97 (0.46, 0.88)           1.00 (0.93, 1.00)         0.77 (0.46, 0.85)           1.00 (0.93, 1.00)         0.77 (0.46, 0.85)           1.00 (0.83, 1.00)         0.98 (0.65, 0.68)           1.00 (0.83, 1.00)         0.77 (0.46, 0.85)	Sensitivity (95% CI) 0 0/2 0/4 0/6 0/8 1 Sensitivity (95% CI) 0 0/2 0/4 0/6 0/8 1 Sensitivity (95% CI)	Specificity (95% CI)
Study Schnidt WA. 1997. Lear CJ. 2002 Nesher G. 2002 Sahvarani C. 2002 Murgatory H. 2003 Reinhard M. 2004 Zaragoza Garcia JM. 201 JS. (" <b>'halo'' sign</b> : Study Lear CJ. 2002 Zaragoza Garcia JM. 201 JS. ( <b>'halo'' sign</b> : Study Schnidt WA. 1997.	07 ± <b>S1</b> 07 ± <b>S1</b>	TP 16 6 6 22 4 ten TP 7 5 ten TP 20 20	FP 2 2 9 9 15 5 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 1 5 0 FN 5 0 FN 5 1 2 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 14 12 10 10 10 10 10 10 10 10 10 10 10 10 10	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 1.0 0.47 [0.16, 0.6 0.40 [0.16, 0.6 0.46 [0.42, 1.0 0.66 [0.42, 1.0 0.67 [0.48, 0.8 0.68 [0.28, 0.9 1.00 [0.48, 1.0 0.58 [0.28, 0.8 1.00 [0.48, 1.0 0.58 [0.28, 0.8 1.00 [0.48, 1.0 0.58 [0.28, 0.8] 1.00 [0.48, 1.0 0.58 [0.28, 0.8] 1.00 [0.48, 1.0 0.58 [0.28, 0.8] 1.00 [0.48, 1.0 0.58 [0.28, 0.8] 1.00 [0.48, 1.0]	3)         Specificity (95% CI           21         0.92 (0.75, 0.99)           0.92 (0.75, 0.99)         0.92 (0.74, 0.99)           0.92 (0.76, 0.99)         0.92 (0.76, 0.98)           0.93 (0.68, 0.88)         0.97 (0.68, 0.88)           0.93 (0.68, 0.88)         0.93 (0.68, 1.00)           10         Specificity (95% CI           11         Specificity (95% CI           12         Specificity (95% CI           13         Specificity (95% CI           14         Specificity (95% CI           15         Specificity (95% CI           16         Specificity (95% CI	Sensitivity (95% CI)	Specificity (95% CI 0 0 2 0 4 0 6 0 8 Specificity (95% CI 0 0 2 0 4 0 6 0 8 Specificity (95% CI 0 0 2 0 4 0 6 0 8
Study Schmidt VX.1997 Leasr CJ. 2002 Nesher O. 2002 Salvarani C. 2002 Murgatory H. 2003 Renhard M. 2004 Zaragoza Garcia JM. 201 Zaragoza Garcia JM. 201 JS. ("Hallo" sign : Study Schmidt VX.1997 Fideensuer K. 2003	07 ± S1	TP 16 6 7 6 6 22 4 ten TP 7 5 ten TP 20 30 7	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 1 5 0 0 FN 5 0 FN 5 1 2 9 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 14 12 10 10 10 00 TN 22 28 8 55 15 10	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 1.0 0.78 [0.42, 0.0 0.40 [0.16, 0.6 0.66 [0.42, 1.0 0.67 [0.48, 0.9 0.67 [0.48, 0.9 0.68 [0.28, 0.9 1.00 [0.48, 1.0 25 [0.28, 0.9 1.00 [0.48, 1.0 25 [0.76, 1.0 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76 [0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 1.0] [0.76, 0.95 [0.76, 0.95 [0.76, 0.95 [0.76, 0.95 [0.76, 0.95 [0.76, 0.95 [0.76, 0.95 [0.76, 0.9	3) Specificity (95% CI)           2) 0.92 (0.75, 0.99)           0.92 (0.76, 0.99)           0.92 (0.76, 0.99)           0.93 (0.74, 0.99)           0.97 (0.66, 0.88)           0.97 (0.66, 0.88)           0.93 (0.66, 1.09)           0.93 (0.66, 1.00)           0.93 (0.66, 1.00)           1.00 (0.93, 1.00)           0.77 (0.46, 0.88)           1.00 (0.93, 1.00)           0.77 (0.46, 0.85)           1.00 (0.83, 1.00)           0.77 (0.46, 0.85)           1.00 (0.83, 1.00)           0.98 (0.65, 0.63)           0.98 (0.65, 0.65)           0.98 (0.65, 0.65)           0.98 (0.65, 0.65, 0.93)	Sensitivity (95% CI)	Specificity (95% C)
Sudy Schmidt Sign) Schmidt WA. 1997 Leasr CJ. 2002 Nesher G. 2002 Salvarani C. 2002 Murgatoyd H. 2003 Renhard M. 2004 Zaragoza Garcia JM. 201 JS. ("Halo" sign : Study Zaragoza Garcia JM. 201 JS. ("halo" sign : Study Schmidt WA. 1997 Pridenhauer K. 2003 Pridenhauer K. 2003	07 ± <b>SI</b> ± <b>SI</b>	TP 16 6 7 6 6 22 4 ten TP 7 5 ten TP 20 30 7 1 1 1 1 1 1 1 1 1 1 1 1 1	FP 2 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 1 1 1 1 1 1 5 0 0 FN 5 0 0 FN 5 0 0 FN 5 2 6	TN 24 23 14 56 13 14 12 10 10 10 10 00 TN 22 28 15 56	Sensitivity (95% C 0.76 (0.53, 0.9 0.86 (0.42, 1.0 0.78 (0.42, 1.0 0.78 (0.40, 0.9 0.40 (0.16, 0.6 0.86 (0.42, 1.0 0.87 (0.48, 0.9 0.80 (0.28, 0.9 0.80 (0.28, 0.9 0.80 (0.28, 0.9 0.80 (0.28, 0.9 0.98 (0.28, 0.9) 0.98 (0.28, 0.9) 0.98 (0.28, 0.9) 0.98 (0.28, 0.9) 0.98 (0.28, 0.9) 0.99 (0.28, 0.9) 0.99 (0.28, 0.9) 0.91 (0.28, 0.9) 0.21 (0.09, 0.3)	3)         Specificity (95% CI           20         92 (0.75, 0.99)           0.92 (0.74, 0.99)         0.92 (0.74, 0.99)           0.92 (0.76, 0.98)         0.93 (0.68, 0.83)           0.79 (0.68, 0.83)         0.79 (0.68, 0.83)           0.93 (0.68, 0.83)         0.93 (0.68, 1.00)           0.93 (0.68, 1.00)         0.92 (0.64, 1.00)           0.93 (0.68, 1.00)         0.92 (0.64, 1.00)           0.93 (0.68, 0.03)         0.97 (0.68, 0.95)           10         Specificity (95% CI)           11         Specificity (95% CI)           12         Specificity (95%, 0.66)           13         Specificity (95%, 0.66)           14         0.85 (0.65, 0.66)           15         1.00 (0.78, 1.00)	Sensitivity (95% CI)	Specificity (95% CI)
Schridto Sign) Schridt WA. 1997 Leasr CJ. 2002 Nesher G. 2002 Saharani C. 2002 Murgatoryd H. 2003 Reinhard M. 2004 Zaragoza Garcia JM. 201 Zaragoza Garcia JM. 201 Zaragoza Garcia JM. 201 Zaragoza Garcia JM. 201 Schmidt WA. 1997 Phdenhauer K. 2003 Reinhard M. 2004 Reinhard M. 2004 Reinhard M. 2004 Reinhard M. 2004	07 ± SI 07 ± SI	TP 16 6 6 22 4 ten TP 7 5 ten TP 20 30 7 21	FP 2 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 1 1 1 1 1 5 0 <b>is</b> ) FN 5 0 <b>is</b> ) FN 5 0 <b>is</b> ) FN 5 0 4	TN 24 23 14 56 13 14 12 10 10 TN 20 10 10 TN 22 28 15 42	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 0.0 0.40 [0.16, 0.6 0.66 [0.42, 1.0 0.77 [0.40, 0.0 0.67 [0.44, 0.0 0.67 [0.44, 0.0 0.69 [0.28, 0.9 1.00 [0.28, 0.9 1.00 [0.46, 1.0 Sensitivity (95% C 0.55 [0.76, 1.0 0.91 [0.76, 0.0 0.21 [0.09, 0.0 0.41 [0.64, 0.0 0.41 [0.64, 0.0	3)         Specificity (95% CI)           21         0.52 (0.75, 0.69)           0.92 (0.74, 0.99)         0.92 (0.74, 0.99)           0.93 (0.74, 0.99)         0.93 (0.66, 0.88)           0.93 (0.66, 0.88)         0.93 (0.66, 1.00)           0.93 (0.66, 1.00)         0.92 (0.64, 1.00)           0.93 (0.66, 1.00)         0.92 (0.64, 1.00)           0.93 (0.66, 1.00)         0.97 (0.46, 0.89)           1.00 (0.93, 1.00)         0.77 (0.46, 0.89)           1.00 (0.93, 1.00)         0.77 (0.46, 0.89)           9.         0.93 (0.65, 0.83)           9.         0.92 (0.65, 0.83)           9.         0.02 (0.76, 0.93)           9.         0.02 (0.85, 0.03)           9.         0.92 (0.86, 1.00)	Sensitivity (95% C) 0 0.2 0.4 0.6 0.8 1 Sensitivity (95% C) 0 0.2 0.4 0.6 0.8 1	Specificity (95% C)
Study     Schmidt WA. 1997     Lear CJ. 2002     Nesher G. 2002     Nesher G. 2002     Savarani C. 2002     Murgatory H. 2003     Reinhard M. 2004     Zaragoza Garcia JM. 201     Study     Lear CJ. 2002     Zaragoza Garcia JM. 201     Study     Study     Study     Study     Schmidt WA. 1997     Schmidt WA. 1997     Schmidt WA. 1997     Schmidt WA. 1997     Reinhard M. 2004     Reinhard M. 2004     Reinsre M. 2005     Schmidt W. 2005     Schmidt WA. 2007     Schmidt WA. 2007     Schmidt WA. 2007     Schmidt WA. 2004     Reinhard M. 2004     Reinhard M. 2004     Reinhard M. 2004     Schmidt WA. 2005	07 ± <b>SI</b> ± <b>SI</b>	TP 16 6 22 4 TP 7 5 ten TP 20 30 7 21 74	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 1 1 5 0 FN 5 0 <b>is</b> ± FN 1 3 26 4 27	TN 24 23 14 56 13 14 12 10 TN 20 10 10 TN 22 28 15 42 192	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 0.0 0.40 [0.16, 0.6 0.66 [0.42, 1.0 0.47 [0.16, 0.6 0.67 [0.48, 0.0 0.67 [0.48, 0.0 0.67 [0.48, 0.0 0.56 [0.28, 0.0 1.00 [0.48, 1.0 0.55 [0.76, 1.0 0.51 [0.77, 0.0 0.51 [0.77, 0.0 0.51 [0.76, 0.0 0.21 [0.09, 0.3 0.48 [0.64, 0.0 0.73 [0.64, 0.0	1) Specificity (95% CI 2) 0.92 (0.75, 0.99 0.92 (0.74, 0.99 0.92 (0.74, 0.99 0.97 (0.66, 0.88 0.79 (0.66, 0.88 0.96 (0.43, 0.07 0.93 (0.66, 1.00 0.92 (0.64, 1.00 0.92 (0.64, 1.00 0.92 (0.64, 1.00 0.77 (0.46, 0.95 1.00 (0.83, 1.00 0.77 (0.46, 0.95 1.00 (0.65, 0.83 0.02 (0.65, 0.83 1.00 (0.78, 1.00 0.98 (0.65, 0.83 1.00 (0.78, 1.00 0.98 (0.68, 1.00 0.98 (0.68, 0.74) 1.96 (0.63, 0.74) 1.96	Sensitivity (95% CI) 0 0.2 04 06 0.8 1 Sensitivity (95% CI) 0 0.2 04 06 0.8 1 Sensitivity (95% CI) 0 0.2 04 06 0.8 1	Specificity (95% C)
Study Schmidt Sign) Schmidt WA. 1997 Lesar CJ. 2002 Nesher O. 2002 Saharani C. 2002 Murgatoyi H. 2003 Reinhard M. 2004 Zaragoza Garcia JM. 201 JS ("halo" sign : Study Zaragoza Garcia JM. 201 JS ("halo" sign : Study Schmidt WA. 1997 Pladenhauer K. 2003 Reinhard M. 2004 Remark JM. 2016	)7 ± <b>SI</b> ± <b>SI</b> 4	TP 16 6 7 6 6 22 4 ten TP 7 5 ten TP 20 30 7 21 74	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 9 1 11 11 1 1 1 1 5 0 <b>is</b> ± FN 5 26 4 27	TN 24 23 14 56 13 14 12 12 10 10 10 10 10 10 10 10 10 10 10 10 10	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 1.0 0.78 [0.42, 0.9 0.40 [0.16, 0.6 0.66 [0.42, 1.0 0.67 [0.48, 0.0 0.67 [0.48, 0.0 0.67 [0.48, 0.0 0.67 [0.48, 1.0 0.56 [0.28, 0.9 1.00 [0.48, 1.0 0.56 [0.76, 1.0 0.51 [0.76, 0.9 0.25 [0.76, 1.0 0.9 [0.76, 0.9 0.21 [0.09, 0.3 0.48 [0.64, 0.8	3)         Specificity (95% CI           21         0.52 (0.75, 0.99)           0.52 (0.74, 0.99)         0.92 (0.74, 0.99)           0.52 (0.74, 0.99)         0.92 (0.74, 0.99)           0.70 (0.66, 0.88)         0.70 (0.66, 0.88)           0.93 (0.66, 1.03)         0.93 (0.66, 1.03)           0.93 (0.66, 1.00)         0.92 (0.64, 1.00)           1.00 (0.92, 10.64, 1.00)         0.97 (0.46, 0.95)           1.00 (0.83, 1.00)         0.77 (0.46, 0.95)           1.00 (0.85, 10.00)         0.77 (0.46, 0.95)           1.00 (0.65, 0.63)         91 (0.06, 0.68)           0.92 (0.65, 0.83)         91 (0.00, 0.78, 1.00)           2.0 (0.98, 10.00)         0.89 (0.88, 1.04)           2.0 (0.99 (0.63, 0.74)         0.69 (0.63, 0.74)	Sensitivity (95% CI) 0 0.2 0/4 0/6 0/8 1 Sensitivity (95% CI) 0 0.2 0/4 0/6 0/8 1 Sensitivity (95% CI) 0 0.2 0/4 0/6 0/8 1	Specificity (95% CI 0 0.2 0.4 0.6 0.8 Specificity (95% CI 0 0.2 0.4 0.6 0.8 Specificity (95% CI 0 0.2 0.4 0.6 0.8
Suby Schmidt WA, 1997 Lear CJ, 2002 Nesher G, 2002 Salvaran C, 2002 Murgatory H, 2003 Reinhard M, 2004 Zangoza Garcia JM, 201 Zangoza Garcia JM, 201 JS ("thato" sign : Study Lear CJ, 2002 Zangoza Garcia JM, 201 JS ("thato" sign : Study Schmidt WA, 1997 Phdenbauer K, 2003 Schmidt WA, 1997 Phdenbauer K, 2003 Romera vIRegas A, 200 Lugman K, 2016	)7 ± <b>S1</b> )7 ± <b>S1</b> 4	TP 16 6 7 6 6 22 4 ten TP 7 5 ten TP 20 30 7 21 74	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 9 1 11 11 1 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 14 12 12 10 10 10 10 10 10 10 10 10 10 10 10 10	Sensitivity (95% c 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 1.0 0.78 [0.42, 0.0 0.40 [0.18, 0.6 0.60 [0.42, 0.0 0.40 [0.18, 0.6 0.67 [0.42, 0.0 0.60 [0.28, 0.0 1.00 [0.48, 1.0 <b>Sensitivity (95% c</b> 0.95 [0.28, 0.6 1.00 [0.48, 1.0 <b>Sensitivity (95% c</b> 0.95 [0.76, 1.0 0.91 [0.76, 0.0 0.91 [0.76, 0.0 0.91 [0.76, 0.0 0.91 [0.76, 0.0 0.71 [0.64, 0.8 0.73 [0.64, 0.8 0.75 [0.64, 0.8 0.73 [0.64, 0.8]	1) Specificity (95% CI 2) 0.92 (0.75, 0.99 0.92 (0.74, 0.99 0.92 (0.74, 0.99 0.92 (0.74, 0.99 0.97 (0.66, 0.88 0.79 (0.66, 0.88 0.79 (0.66, 0.88 0.79 (0.66, 0.88 0.79 (0.66, 0.88 0.92 (0.64, 1.00) 1) Specificity (95% CI 1) 0.00 (0.33, 1.00) 0.77 (0.46, 0.85 0.77 (0.46, 0.85 1) 0.00 (0.55, 0.96 8) 0.82 (0.56, 0.96 8) 0.98 (0.63, 0.74 4) 0.98 (0.63, 0.74 5) 0.99 (0.63, 0.74	Sensitivity (95% CI) 0 0/2 0/4 0/6 0/8 1 Sensitivity (95% CI) 0 0/2 0/4 0/6 0/8 1 0 0/2 0/	Specificity (95% CI 0 0.2 0.4 0.6 0.8 Specificity (95% CI 0 0.2 0.4 0.8 0.8 0.8 Specificity (95% CI 0 0.2 0.4 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8
Study Schmidt Stypi, UKA 1997 Lesar CJ. 2002 Nesher G. 2002 Saharani C. 2002 Murgatoyd H. 2003 Reinhard M. 2004 Zaragoza Garcia JM. 201 Zaragoza Garcia JM. 201 JS ("halo" sign : Study Lesar CJ. 2002 Zaragoza Garcia JM. 201 Study Schmidt WA. 1997 Pedenhauer K. 2003 Reinhard M. 2004 Romera-Wilegas A. 200 Lugmani R. 2015	07 ± SI 507 ± SI 4	TP 16 6 6 22 4 TP 7 5 TP 7 5 TP 20 30 7 21 74 FP	FP 2 2 9 9 15 5 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 14 12 12 TN 20 10 10 TN 22 28 15 42 192 Se	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 0.0 0.40 [0.16, 0.6 0.66 [0.42, 1.0 0.47 [0.16, 0.6 0.66 [0.42, 0.0 0.67 [0.48, 0.0 0.67 [0.48, 0.0 0.67 [0.48, 0.0 0.56 [0.26, 0.5 0.56 [0.26, 0.0 0.56 [0.76, 0.0 0.51 [0.56, 0.0] 0.5	1) Specificity (95% CI 2) 0.92 (0.75, 0.99 0.92 (0.74, 0.99 0.92 (0.74, 0.99 0.97 (0.66, 0.88 0.97 (0.66, 0.88 0.97 (0.66, 0.88 0.92 (0.64, 1.00 0.92 (0.64, 1.00 0.92 (0.64, 1.00 0.92 (0.64, 1.00 0.92 (0.64, 1.00 0.97 (0.46, 0.95) 1.00 (0.83, 1.00 0.77 (0.46, 0.95) 1.00 (0.78, 100 0.95 (0.65, 0.83 9) 0.98 (0.65, 0.83 9) 0.98 (0.65, 0.83 9) 0.98 (0.65, 0.83 9) 0.98 (0.65, 0.74) 1.09 (0.78, 1.00 1.09 (0.78, 1.00 1.09 (0.78, 1.00 1.09 (0.78, 1.00) 1.09 (0.78, 1.00) 1.00 (0.78, 1.	Sensitivity (95% CI) 0 0.2 0/4 0/6 0/8 1 Sensitivity (95% CI) 0 0.2 0/4 0/6 0/8 1 Sensitivity (95% CI)	Specificity (95% CI)
C (*faild Sign)         1           Study         Schmidt WA. 1997           Schmidt WA. 1997         Leaar CJ. 2002           Nesher O. 2002         Salvarani C. 2002           Murgatory H. 2003         Renhard M. 2004           Zarayoza Garcia JM. 201         Zarayoza Garcia JM. 201           JS (*fhalo" sign :         Study           Leaar CJ. 2002         Zarayoza Garcia JM. 201           JS (*fhalo" sign :         Study           Schmidt WA. 1997         Pridenhauer K. 2003           Peridenhauer K. 2003         Reimark M. 2016           VIRI         Study           Study         Study           Bergina K. 2003         Reimark M. 2016           WIRI         Study           Study         1	07 ± S1 5 6	TP 16 6 22 4 TP 7 5 ten TP 20 30 7 21 74 FP 2 2 2 7 4 TP 20 30 7 21 7 4 TP 20 30 7 21 7 4 5 5 5 5 5 5 5 5 5 5 5 5 5	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 9 1 11 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 13 14 12 78 20 10 10 10 10 10 10 10 10 10 10 10 10 10	Sensitivity (95% cf) 0.76 [0.52, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 0.0 0.40 [0.18, 0.6 0.66 [0.42, 1.0 0.60 [0.28, 0.9 Sensitivity (95% c 0.58 [0.28, 0.9 1.00 [0.48, 1.0] Sensitivity (95% c 0.58 [0.76, 1.0] 0.73 [0.64, 0.8 0.73 [0.64, 0.8 0.73 [0.64, 0.8] 1.00 [0.48, 1.00]	1) Specificity (95% CI) 2) 0.92 (0.75, 0.99 0.92 (0.74, 0.99 0.92 (0.74, 0.99 0.92 (0.74, 0.99 0.95 (0.74, 0.99 0.95 (0.45, 0.98 0.79 (0.66, 0.88 0.97 (0.66, 0.88 0.97 (0.66, 0.88 0.92 (0.64, 1.00 0.92 (0.64, 1.00 0.92 (0.64, 1.00 0.92 (0.64, 1.00 0.95 (0.65, 0.95 0.95 (0.65, 0.95) 0.95 (0.65, 0.95 0.95 (0.65, 0.95) 0.95 (0.65, 0.95 0.95 (0.65, 0.95) 0.95 (0.65, 0.95	Sensitivity (95% CI)	Specificity (95% C)
C (*faild Sign)         35           Study         Schmidt WA. 1997.           Schmidt WA. 1997.         Lesar CJ. 2002           Nesher G. 2002         Sahvarani C. 2002           Sahvarani C. 2002         Zaragoza García JM. 201           Zaragoza García JM. 201         Zaragoza García JM. 201           JS (**** Lasar CJ. 2002         Zaragoza García JM. 201           Zaragoza García JM. 201         Study           JS (***** Lasar CJ. 2002         Zaragoza García JM. 201           Pádenhauer K. 2003         Reinhard M. 2004           Reinhard M. 2004         Study           Study         Lugmani R. 2016           VIRI         Study         1           Biey TA. 2005         Biey TA. 2007         1	07 ± SI 07 ± SI 4 4	TP 16 6 7 6 6 22 4 <b>ten</b> TP 7 5 <b>ten</b> TP 20 30 7 21 74 FP 2 3 2 2 2 1 4	FP 2 2 2 2 9 9 15 5 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 13 14 12 10 10 10 10 10 10 10 10 10 10 10 10 10	Sensitivity (95% cf) 0.76 (0.53, 0.9 0.86 (0.42, 1.0 0.78 (0.42, 0.0 0.46 (0.42, 1.0 0.46 (0.42, 1.0 0.46 (0.42, 0.0 0.46 (0.42, 0.0 0.46 (0.42, 0.0 0.46 (0.42, 0.0 0.46 (0.46, 1.0 0.46 (0.46, 1.0 0.47 (0.46, 1.0 0.41 (0.46, 1.0 0.47 (0.46, 1.0 0.47 (0.46, 1.0 0.47 (0.46, 1.0 0.47 (0.46, 1.0 0.47 (0.46, 1.0) 0.49 (0.46, 0.0 0.49 (0.46, 0.0) 1.00 (0.46, 1.0) 0.49 (0.46, 0.0) 1.00 (0.46, 0.0) 0.40 (0.	1) Specificity (95% CI) 2) 0.92 (0.75, 0.94) 0.92 (0.74, 0.99) 0.92 (0.74, 0.99) 0.92 (0.74, 0.99) 0.97 (0.66, 0.88) 0.96 (0.43, 0.87) 0.93 (0.66, 1.00) 0.92 (0.64, 1.00) 0.92 (0.64, 1.00) 0.92 (0.64, 1.00) 0.97 (0.64, 0.85) 0.97 (0.64, 0.85) 0.97 (0.64, 0.85) 0.97 (0.64, 0.85) 0.97 (0.64, 0.85) 0.92 (0.65, 0.93) 1.00 (0.78, 1.00) 0.98 (0.65, 0.93) 1.00 (0.78, 0.05) 1.00 (0.78, 0.05) 1.00 (0.78, 0.05) 1.00 (0.78, 0.05) 2.00 (0.95, 0.95) 3.00 (0.15, 0.95) 0.77 (0.34, 0.44) 3.04 (0.15, 0.95) 0.77 (0.34, 0.44) 3.04 (0.15, 0.95) 3.05 (0.15, 0.95) 3.04	Sensitivity (95% C)	Specificity (95% CI)
Study Schmidt VX.1997 Leaar CJ.2002 Nesher O.2002 Sahvarani C. 2002 Murgatory H. 2003 Renhard M. 2004 Zaragoza Garcia JM. 201 Zaragoza Garcia JM. 201 Leaar CJ. 2002 Zaragoza Garcia JM. 201 Leaar CJ. 2002 Zaragoza Garcia JM. 201 Renhard M. 2004 Renhard M. 2004 Renhard M. 2004 Renhard M. 2004 Renhard M. 2004 Buey TA. 2005 Biey TA. 2005 Biey TA. 2005	07 ± SI 07 ± SI 4 4	TP 16 6 6 22 4 TP 7 5 ten TP 20 30 7 21 7 4 FP 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2	FP 2 2 2 9 9 15 5 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 14 12 TN 20 10 10 TN 22 28 15 42 192 Se	Sensitivity (95% C 0.76 (0.53, 0.9 0.86 (0.42, 1.0 0.78 (0.42, 0.0 0.78 (0.42, 0.0 0.68 (0.42, 1.0 0.78 (0.42, 0.0 0.67 (0.44, 0.0 0.67 (0.44, 0.0 0.67 (0.44, 0.0 0.68 (0.28, 0.9 1.00 (0.48, 1.0) 0.91 (0.54, 0.0 0.73 (0.64, 0.0 0.73 (0.76, 0.0) 0.91 (0.70, 0.99)	3) Specificity (95% C1)           2) 0.92 (0.75, 0.98)           0.92 (0.74, 0.99)           0.92 (0.74, 0.99)           0.93 (0.74, 0.99)           0.97 (0.66, 0.88)           0.97 (0.66, 0.88)           0.97 (0.66, 0.88)           0.98 (0.64, 0.08)           0.93 (0.66, 1.00)           0.93 (0.66, 1.00)           0.95 (0.64, 1.00)           0.95 (0.64, 0.08)           1.00 (0.93, 1.00)           0.77 (0.46, 0.89)           0.93 (0.65, 0.93)           1.00 (0.77, 10.46, 0.89)           0.94 (0.66, 0.83)           0.94 (0.66, 0.93)           0.95 (0.65, 0.93)           1.00 (0.78, 1.00)           0.95 (0.65, 0.93)           1.00 (0.78, 1.00)           0.95 (0.63, 0.74)           5pecificity (95% C1)           0.95 (0.63, 0.74)           5pecificity (0.95% C1)           0.95 (0.70, 0.93)           0.95 (0.70, 0.93)	Sensitivity (95% CI)	Specificity (95% C)
Study           Schmidt Sign)           Schmidt WA. 1997           Lesar CJ. 2002           Nesher G. 2002           Sahvarani C. 2002           Murgatory H. 2003           Reinhard M. 2004           Zarapoza Garcia JM. 201           JS ("Halo" sign :           Study           Lesar CJ. 2002           Zarapoza Garcia JM. 201           JS ("Halo" sign :           Study           Schmidt WA. 1997           Pidenhauer K. 2007           Pidenhauer K. 2008           Biey TA. 2005           Biey TA. 2007           Geiger J. 2010           GrinkT. 2014	07 ± S1 07 ± S1 4 (P) ( 19 10 38 5 10 38 5 5 5 5 5 5 5 5 5 5 5 5 5	TP 16 6 6 22 4 TP 7 5 TP 20 30 7 21 74 FP 2 3 2 9 2 9 2 1 1 1 1 1 1 1 1 1 1 1 1 1	FP 2 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 1 11 1 1 1 1 1 1 1 1 1 1 1	TN 24 23 14 56 13 14 12 TN 20 10 TN 22 28 15 42 192 Se	Sensitivity (95% C 0.76 [0.53, 0.9 0.86 [0.42, 1.0 0.78 [0.42, 1.0 0.78 [0.42, 1.0 0.78 [0.42, 1.0 0.40 [0.18, 0.6 0.47 [0.48, 0.0 0.67 [0.48, 0.0 0.67 [0.48, 0.0 0.58 [0.28, 0.0 1.00 [0.48, 1.0 0.58 [0.28, 0.0 1.00 [0.48, 1.0 0.59 [0.76, 1.0 0.59 [0.76, 1.0 0.59 [0.76, 1.0 0.51 [0.576, 1.0 0.57 [0.586, 0.587] 0.57 [0.586, 0.5	1) Specificity (95% CT) 2) 0.92 (0.75, 0.94) 0.92 (0.74, 0.99) 0.92 (0.74, 0.99) 0.92 (0.74, 0.99) 0.92 (0.74, 0.99) 0.92 (0.64, 0.86) 0.79 (0.66, 0.86) 0.92 (0.64, 1.00) 0.92 (0.64, 1.00) 1.00 (0.93, 1.00) 0.92 (0.64, 0.95) 1.00 (0.93, 1.00) 0.95 (0.65, 0.96) 0.95 (0.65, 0.96) 0.95 (0.65, 0.96) 1.00 (0.95 (0.76, 1.00) 5) 0.98 (0.63, 0.74) 5) 0.99 (0.63, 0.74) 5) 0.90 (0.76, 0.94) 5) 0.90 (0.76,	Sensitivity (95% CI)	Specificity (95% C) 0 0.2 0.4 0.6 0.8 Specificity (95% C) 0 0.2 0.4 0.6 0.8 Specificity (95% C) 0 0.2 0.4 0.6 0.8 Specificity (95% C) Specificity (95% C)
Study           Schmidt Stypi, J.           Schmidt WA. 1997.           Leasr CJ. 2002           Nesher G. 2002           Saharani C. 2002           Murgatoryd H. 2003           Renhard M. 2004           Zaragoza Garcia JM. 2014           Zaragoza Garcia JM. 2014           Zaragoza Garcia JM. 2012           Zaragoza Garcia JM. 2012           Zaragoza Garcia JM. 2012           Zaragoza Garcia JM. 2014           Reinhard M. 2004           Reinhard M. 2004           Reinhard M. 2004           Reinhard M. 2004           Big Ying Schmidt WA. 1997           Study           Study	07 ± <b>S1</b> 07 ± <b>S1</b> 10 98 25 98	TP 16 6 6 22 4 TP 7 5 TP 20 30 7 21 74 FP 2 3 2 9 0 1 1 1 1 1 1 1 1 1 1 1 1 1	FP 2 2 9 9 15 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	FN 5 1 2 9 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	TN 244 233 144 156 133 144 12 200 100 100 100 100 100 100 100 100	Sensitivity (95% C 0.76 (0.53, 0.9 0.86 (0.42, 1.0 0.78 (0.42, 0.0 0.78 (0.42, 0.0 0.67 (0.44, 0.0 0.67 (0.44, 0.0 0.67 (0.44, 0.0 0.67 (0.44, 0.0 0.66 (0.28, 0.0 1.00 (0.46, 1.0 0.95 (0.76, 1.0 0.95 (0.76, 1.0 0.95 (0.76, 1.0 0.95 (0.76, 1.0 0.91 (0.54, 0.0 0.73 (0.64, 0.0 0.73 (0.64, 0.0 0.73 (0.64, 0.0 0.73 (0.64, 0.0 0.73 (0.64, 0.0 0.73 (0.64, 0.0 0.91 (0.79, 1.00) 0.91 (0.79, 1.00) 0.91 (0.79, 1.00) 0.91 (0.79, 1.00) 0.95 (0.70, 0.99) 1.00 (0.46, 1.00) 0.91 (0.70, 0.99) 0.91 (0.59, 1.00) 0.95 (0.70, 0.99) 0.95 (0.70, 0.95) 0.95 (0.70, 0.95) 0.95 (0.70, 0.95) 0.95 (0.70, 0.95	1) Specificity (95% CI) 2) 0.92 (0.75, 0.96) 0.92 (0.74, 0.99) 0.92 (0.74, 0.99) 0.92 (0.74, 0.99) 0.97 (0.66, 0.88) 0.96 (0.43, 0.87) 0.93 (0.66, 1.00) 0.92 (0.64, 1.00) 1.00 (0.83, 1.00) 0.77 (0.46, 0.89) 1.00 (0.83, 1.00) 0.77 (0.46, 0.89) 1.00 (0.83, 1.00) 0.95 (0.65, 0.83) 1.00 (0.76, 1.04) 1.08 (0.85, 0.05) 0.98 (0.65, 0.83) 1.00 (0.76, 0.94) 1.05 (0.65, 0.83) 1.00 (0.76, 0.94) 1.05 (0.76, 0.95) 0.73 (0.36, 0.95) 0.74 (0.37, 0.36) 0.75 (0.75, 0.95) 0.75 (0.37, 0.36) 0.75 (0.75, 0.35) 0.75 (0.37, 0.36) 0.75 (0.75, 0.35) 0.75 (0.37, 0.36) 0.75 (0.75, 0.35) 0.75	Sensitivity (95% C)	Specificity (95% C)

**Figure 1** (A) Diagnostic performance of different ultrasound (US) signs of vasculitis and MRI studies in comparison with clinical diagnosis as reference standard. (B) Diagnostic performance of different US signs of vasculitis and MRI studies in comparison with temporal artery biopsy as reference standard. TP, true positives; FP, false positives; FN, false negatives; TN, true negatives.

No study was identified addressing the role of MRI for the evaluation of extracranial LV-GCA.

One study<sup>55</sup> (n=30, low RoB) investigated MRA for the diagnosis of TAK using conventional angiography as the reference standard (see table 4 and online supplementary tables S3 and S6 for further details). A sensitivity of 100% (95% CI 76 to 100) and a specificity of 100% (95% CI 63 to 100) for MRA was reported.

#### <sup>18</sup>F-FDG positron emission tomography

Only two studies<sup>41 42</sup> (n=93, one study with low RoB<sup>42</sup>) focused on the diagnostic performance of 18F-FDG-PET for the diagnosis of extracranial LV-GCA yielding sensitivities of 67%-77% and specificities of 66%-100%, using TAB or a clinical diagnosis after 6 months as reference standards, respectively. The study by Lariviere *et al*<sup>42</sup> (n=24, low RoB), reporting a specificity of 100%, applied

a semiquantitative approach (aortic-to-blood pool uptake ratio) for the evaluation of <sup>18</sup>F-FDG vessel wall uptake (table 5 and online supplementary table S4 for further study details, online supplementary table S6 for RoB assessment).

#### CT angiography

The study by Lariviere *et al* mentioned above<sup>42</sup> (n=25, with low RoB) evaluated the roles of PET and CTA within the same population. CTA revealed a sensitivity of 73% (95% CI 45 to 92) and a specificity of 78% (95% CI 40 to 97) using the clinical diagnosis of GCA after 6 months as reference standard.

For the diagnosis of TAK, one study<sup>56</sup> (n=25, with low RoB) examined the role of CTA reporting a sensitivity of 100% (95% CI 76 to 100) and a specificity of 100% (95% CI 40 to 100) compared with conventional angiography (table 5 and online supplementary tables S5 for further study details, online supplementary table S6 for RoB assessment).

# Outcome prediction, monitoring disease activity and damage and technical aspects of imaging techniques

Description of observations without inferences in monitoring studies (n=11) and studies on technical aspects (n=5) as well as heterogeneity in study design, outcomes and technical settings of prognostic studies (n=5) precluded any meta-analysis. Main study characteristics and findings are summarised in online supplementary tables S7–S10.

Five studies investigated the role of US,<sup>43</sup> <sup>44</sup> <sup>18</sup>F-FDG-PET<sup>45</sup> <sup>46</sup> or CT<sup>47</sup> for outcome prediction in GCA (online supplementary table S7) with none of them being appraised at low RoB (online supplementary table S8). GCA characteristic US lesions at baseline did not predict a relapse,<sup>44</sup> and the risk of ischaemic complications was similar in patients with temporal and extracranial LV involvement.<sup>43</sup> The response of <sup>18</sup>F-FDG-uptake to GC therapy (at 3 and 6 months) was not associated with the risk of relapse<sup>45</sup>; however, baseline <sup>18</sup>F-FDG-uptake at the aorta predicted aortic dilatation during long-term disease course according to one study.<sup>46</sup> For TAK, no study was identified addressing the role of imaging for outcome prediction.

For GCA, 13 studies were found investigating the role of imaging for monitoring disease activity and damage.<sup>17 20 22 25 28 29 43-45 48-51</sup> Ten US studies (197 patients, follow-up range: 1–41 months) reported that the 'halo' sign at temporal arteries was no longer detected in the majority of patients after 2–4 weeks of GC therapy,<sup>17 20 22 25 28 29 43 44 48 49</sup> whereas at larger arteries, vessel wall swelling persisted in two thirds of patients according to CT and US studies.<sup>43 51</sup> Additionally, the occurrence of new vasculitic US lesions was reported in up to 10% of GCA patients despite GC treatment.<sup>43 18</sup>F-FDG uptake in the wall of extracranial LVs was comparable in GCA patients in full remission and those with a relapse.<sup>45</sup> In TAK, US and MRI were also not helpful

 Table 3
 Sensitivity analyses for diagnostic studies on ultrasound ('halo' sign) and MRI in comparison with clinical diagnosis for cranial giant cell arteritis (GCA) as reference standard

	Number of patients (number of studies)	LR+ (95% CI)	LR– (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ultrasound					
Halo versus clinical diagnosis (main analysis)*	605 (eight studies) <sup>17 19 20 23 25 28 30 31</sup>	19 (4.8 to 75.5)	0.2 (0.1 to 0.4)	77 (62 to 87)	96 (85 to 99)
Excluding high RoB studies*†	255 (four studies) <sup>25 28 30 31</sup>	16 (7.3 to 35.2)	0.2 (0.1 to 0.3)	86 (76 to 93)	95 (89 to 98)
Studies without GC*	156 (four studies) <sup>19 20 25 28</sup>	4.0 (2.6 to 6.2)	0.3 (0.2 to 0.7)	73 (49 to 89)	82 (75 to 87)
Studies with high resolution device*‡	292 (four studies) <sup>19 25 30 31</sup>	13.8 (3.9 to 48.2)	0.1 (0.1 to 0.3)	87 (77 to 93)	94 (79 to 98)
Suspected diagnosis well-defined§	175 (three studies) <sup>25 28 31</sup>	11.5 (4.5 to 29.2)	0.1 (0.1 to 0.3)	89 (76 to 95)	92 (83 to 97)
Longitudinal studies§	244 (four studies) <sup>19 25 28 31</sup>	7.5 (3.4 to 16.8)	0.1 (0.1 to 0.3)	88 (77 to 94)	88 (78 to 94)
MRI					
MRI versus clinical diagnosis (main analysis)*	509 (six studies) <sup>33–35 38–40</sup>	5.9 (3.4 to 10.3)	0.3 (0.2 to 0.5)	73 (57 to 85)	88 (81 to 92)
Excluding high RoB studies*†	446 (five studies) <sup>33 34 38-40</sup>	6.8 (3.6 to 13)	0.3 (0.1 to 0.6)	75 (56 to 88)	89 (82 to 93)
Studies with high resolution device*‡	260 (four studies) <sup>33 35 39 40</sup>	3.8 (2 to 7.5)	0.4 (0.2 to 0.8)	68 (44 to 85)	82 (69 to 91)
Suspected diagnosis§	270 (three studies) <sup>33 34 38</sup>	8.7 (5 to 15.2)	0.2 (0.1 to 0.3)	82 (74 to 87)	91 (84 to 95)
Longitudinal studies§	411 (three studies) <sup>34 38 40</sup>	7.5 (4.9 to 11.7)	0.3 (0.2 to 0.4)	75 (65 to 84)	90 (85 to 93)

\*Bivariate random-effects binomial generalised mixed model.

†High RoB was defined, in the case of concern on ≥5 RoB items or all 3/3 applicability items out of the QUADAS-2 tool.

‡High resolution devices were defined as >12 MHz probes for ultrasound or 3T MRI machines.

§Univariate random-effects models.

longitudinal studies, studies with clinical diagnosis after follow-up as reference standard; LR, likelihood ratio; QUADAS-2, Quality

Assessment of Diagnostic Accuracy Studies-2; RoB, risk of bias; suspected diagnosis, studies with detailed definition of suspicion of giant cell arteritis included; without GC, studies without glucocorticoid treatment before performance of ultrasound.

to discriminate between active disease and remission<sup>57 58</sup> (see online supplementary table S9 for details on monitoring studies).

All five studies (two on MRI, three on  ${}^{18}\text{F-FDG-PET})^{35}$   ${}^{37}$   ${}^{52-54}$  on technical requirements, settings and operational procedures were performed in GCA patients and are summarised in online supplementary table S10.

#### DISCUSSION

This SLR confirms the good performance of US and MRI for the diagnosis of cranial GCA. The 'halo' sign (US) and increased vessel wall thickness in combination with contrast enhancement (MRI) of superficial temporal arteries, respectively, were the most relevant imaging findings suggesting GCA. Data on imaging for diagnosis of extracranial LV disease remain limited.

The diagnostic performance of US was better in the current than in previous meta-analyses with a higher sensitivity  $(77\% \text{ vs } 55\%-69\%)^{59-61}$  but similar specificity  $(96\% \text{ vs } 89\%-94\%)^{59-61}$  for diagnosis of cranial GCA, which possibly relies on the fact that we included more recent, high-quality studies. A recent SLR conducted

by Buttgereit et al identified many of the same studies described in this work; however, that SLR focused on imaging modalities in GCA and PMR (omitting papers on TAK), spared CT and only reported diagnostic values of individual studies rather than providing meta-analysed estimates on sensitivity and specificity.<sup>62</sup> This is a clear addition of our SLR, together with also covering outcome prediction as well as monitoring disease activity/damage, not addressed in previous SLRs. The sensitivity analyses of the meta-analysis suggest that technical aspects and the definition of study entry criteria have all an impact on the sensitivity of US. Expertise with vascular US (as in any other diagnostic test) is another factor that may influence its diagnostic properties. We could not assess this factor, since all studies were conducted by expert groups. GC treatment before an imaging test has been demonstrated to reduce the sensitivity of the respective imaging modality.<sup>6</sup> <sup>63</sup> Our results do not seem to confirm this observation since the 'halo' was less sensitive for diagnosis of cranial GCA when pooling studies in which patients had not been treated with GCs before US was performed as compared with the main analysis. This finding, however, was largely influenced by a single

6

		RoB		Low	Low	High	High	Mod	High	Mod	Mod		Low
		Elementary lesions		Wall thickening+contrastenhancement score <sup>1-4</sup>	Wall thickening+contrastenhancement score (0–3)	Wall thickening+contrastenhancement score (0–3)	Wall thickening+contrast enhancement (artery wall/temporalmuscle)	Wall thickening+contrastenhancement score (0–3)	Wall thickening+contrastenhancement score (0–3)	TA, occipital [wall thickening+contrastenhancement score (0-3)] intracranial (enhancement)	Wall thickening+contrastenhancement score (0–3)		Luminal changes (stenosis, occlusion, dilatation, aneurysms)
		Investigated structures		TA, occipital	TA, occipital	TA, occipital	Deep TA, temporal muscle	TA, occipital	TA, occipital	TA, occipital, intracranial	TA, occipital		Aorta, brachiocephalic trunk. subclavian.
✓ I × ⊥/	eritis (IAK):	n LV-GCA		RN	R	N	R	RN	RN	щ	щ		
	ayasu art	n TAB+ (%)		5 (56)	21 (78)	11 (73)	61 (100)	14 (100)	62 (63)	(06) 6	31 (23)		NA
	GCA) and Take	n Final diagn GCA/TAK(%)		9 (43)	31 (48)	28 (65)	61 (62)	14 (25)	102 (55)	20 (80)	137 (80)		20 (67)
	giant cell arteritis (	Reference standard		ACR criteria or TAB	Clinical diagn 6m or TAB	ACR criteria or TAB	TAB	TAB	Clinical diagn 6m or TAB	ACR criteria or TAB	ACR criteria (retrospectively confirmed) or TAB or clinical diagn FU (NR)		Conventional angiography
	lostic studies on MHI in cranial	Inclusion criteria		Headache, jaw claudication, TA tenderness/induration/pulse decrement, visual impairment	Headache, TA tenderness, visual impairment, increased APR	Suspected GCA*	Suspected GCA, TAB, MRI deep TA, temporal muscle	Suspected GCA*	Headache, TA tenderness/pulse, APR +MRI and FU available	Suspected GCA	Suspected GCA+TAB		Suspected TAK
	stics of diagn	n female (%)		11 (52)	31 (48) I	30 (70)	68 (69)	34 (62)	125 (68)	21 (84)	126 (74)		27 (90)
	aracteri	۲		21	64	43	66	55	185	25	171		30
	Table 4 Main ch	Study ID	GCA	Bley et al <sup>33</sup>	Bley et al <sup>34</sup>	Geiger <i>et al<sup>35</sup></i>	Veldhoen <i>et al</i> <sup>36</sup>	Franke <i>et al<sup>37</sup></i>	Klink et al <sup>38</sup>	Siemonsen <i>et al</i> <sup>39</sup>	Rhéaume <i>et al</i> <sup>40</sup>	TAK	Yamada <i>et al</i> <sup>55</sup>

"Suspected GCA according to the ACR criteria, no further details described.

number of finally included patients in analysis; NA, not applicable; n female, number of females; n final diagn GCA, number of patients finally diagnosed with GCA; NR, not reported; n LV-GCA, number of GCA patients with large vessel involvement; n TAB+, number of positive temporal artery biopsy results in finally diagnosed GCA patients; RoB, overall appraisal of risk of bias and concerns about applicability (arbitrarily defined) (high, in the case of concern on 25/10 risk of bias items or concern on 3/3 applicability items out of the QUADAS-2 tool; moderate, in case of concern on 4/10 risk of bias items and/or concern on 2/3 applicability items out of the QUADAS-2 tool; moderate, in case of concern on 4/10 risk of bias items and/or concern on 2/3 applicability items out of the QUADAS-2 tool; noderate, in case of concern on 2/10 risk of bias items or concern on 2/3 applicability; items out of the QUADAS-2 tool; noderate, in case of concern on 2/10 risk of bias items or concern on 2/3 applicability; items out of the QUADAS-2 tool; noderate, in case of concern on 2/10 risk of bias items or concern on 2/3 applicability; items out of the QUADAS-2 tool; low, in case of concern on 2/3 RoB and no concern about applicability); Pat, finally included number of patients in analysis; TA, temporal artery/arteries; TAB+, patients with a positive histology ACR, American College of Rheumatology; APR, acute phase reactants; diagn, diagnosis; FU, follow-up; GCA, giant cell arteritis; LV, large vessel; m, months; mod, moderate; MRI, magnetic resonance imaging; n, suggesting vasculitis.

carotid, vertebral

6

	nd Tak	ayasu arteritis (								
Study ID	E	n Female (%)	Inclusion criteria	Reference standard	n Final diagn GCA (%)	n TAB+ (%)	n LV- GCA	Investigated structures	Elementary lesions	RoB
<sup>18</sup> F-FDG PET										
GCA										
Blockmans et al <sup>4</sup>	69	38 (55)	Age ≥45 years, ESR ≥40 mm/h, headache, fever, PMR, weight loss	TAB	13 (19)	13 (100)	Ц	Aorta, carotid, subclavian, femoral, popliteal, tibial	Contrast enhancement (score (0-3)/vascular bed)	poM
Lariviere <i>et al</i> <sup>42</sup>	24	16 (67)	Suspected GCA+TAB	Clinical diagn 6m	15 (63)	6 (40)	RN	Aorta, supra-aortic branches, iliac, femoral	Contrast enhancement (SUV <sub>max</sub> vascular bed/ SUV <sub>mean</sub> blood)	Low
CTA										
GCA										
Lariviere <i>et al</i> <sup>42</sup>	24	16 (67)	Suspected GCA+TAB	Clinical diagn 6m	15 (63)	6 (40)	NR	Aorta, supra-aortic branches	Wall thickening score (0-3)	Low
TAK										
Yamada et a/ <del>s</del> 6	25	NR	Suspected TAK	CA	20 (80)	NA		Aorta, brachiocephalic trunk, subclavian, carotid, pulmonary trunk	Luminal changes wall thickening (>1 mm)+luminal changes	Low
CA, conventional ang not applicable; n fem involvement; n TAB+, about applicability (ar RoB items and/or con specificity; SUV, stand	ograph) le, num number number number of cern on cern on ardised	<i>t;</i> diagn, diagnosi: ber of females; n of positive tempc defined) (high, in t ≥1/3 applicability uptake value; TAI	s; ESR, erythrocyte sedimentat final diagn GCA, number of pat oral artery biopsy results in final the case of concern on ≥5/10 R / items out of the QUADAS-2 to / items out of the apositive hist B+, patients with a positive hist	ion rate; LV, large ients finally diagn ly diagnosed GC toB items or con ol, low, in case o tology suggesting	r vessel; m, mon nosed with GCA A patients; PMF A patients; PMF cern on 3/3 app of concern on ≤3 y vasculitis.	ths; mod, n ; NR, not re 3, polymyale iicability iter /3 risk of bi	noderate ported; jia rheur ms out o as items as items	; n, number of finally inclu n LV-GCA, number of GC/ matica; RoB, overall appra f the QUADAS-2 tool; mo f and no concern about ap ; and no concern about ap	ded patients in analysis; NA A patients with large vessel aisal of risk of bias and conce derate, in case of concern or oplicability); Sens, sensitivity; oplicability); Sens, sensitivity;	4/10 Spec,

study with high RoB and, by exclusion of that particular study, US was more sensitive to diagnose cranial GCA in patients without GCs as compared with the main analysis (83% vs 77%).

The observation that the combination of the US signs 'halo', stenosis and occlusion had a similar sensitivity to the 'halo' sign alone can be explained by the fact that in GCA, vascular stenosis or occlusion is usually caused by inflammatory wall swelling, which is the morphological correlate of the 'halo' sign.<sup>6 17 22-24</sup>

The 'compression' sign, another key elementary US lesion for cranial GCA, revealed a good diagnostic performance in two studies.<sup>30 32</sup> Both studies, however, were published by the same research group and were not completely independent since five patients (Aschwanden M, personal communication) were included in both studies.

The pooled sensitivity (73%) and specificity (88%) of MRI was lower than that of US (77% and 96%, respectively) when the clinical diagnosis was used as the reference standard, while MRI had a higher sensitivity (93% vs 70%) and a similar specificity (81% vs 84%) to sonography when both modalities were compared with TAB. This indirect comparison must be interpreted with caution, because the different test performances are likely also influenced by variations in study design and data analysis. In most MRI studies, for example, TAB was performed in selected cases with high suspicion of GCA only, while in US studies, the majority of patients underwent a TAB. A retrospective study comparing US and MRI directly reported a similar sensitivity (69% and 67%. respectively) and specificity (both with 91%) for both techniques,<sup>64</sup> whereas a prospective direct comparison of both modalities is still missing.

Although PET is commonly used in patients with suspected extracranial LVV, fever of unknown origin or other systemic illnesses, the SLR identified only two prospective studies on this imaging modality<sup>41 42</sup> reporting highly discordant results: in the study of Blockmans et al, data from patients with TAB proven GCA, and PMR with <sup>18</sup>F-FDG uptake in LVs were both considered as GCA cases. This creates 'ground' for circular reasoning given that the test under investigation had also been part of the reference standard.<sup>41</sup> Recalculating the PET data for TAB positive GCA patients yielded a sensitivity of 77% and specificity of 66%, which might be an underestimation of the true diagnostic value of PET, because TAB is frequently false negative in patients with extracranial LV-GCA.<sup>7</sup> Besides, the study by Lariviere et al, which applied the clinical diagnosis after follow-up of 6 months as reference standard, showed a specificity of PET of 100%.42 This divergence underlines that the performance of a diagnostic test is strongly influenced by the reference standard and that such a standard is urgently needed for extracranial LVV in order to facilitate future studies in the field.

Extracranial large arteries are involved in up to 80% of patients with GCA.<sup>8 48 65 66</sup> In one US study, sensitivity

improved by only 2%, when axillary arteries were investigated in addition to temporal arteries, with similar specificity.<sup>31</sup> Since no other studies were available, the diagnostic gain of evaluating different vascular beds with imaging in addition to cranial arteries remains therefore unclear. Additional studies are warranted to clarify whether a standardised hierarchical approach to assess different vascular territories (eg, temporal, carotid, subclavian and axillary arteries) with US or other imaging modalities improves the diagnostic certainty of cranial and extracranial LV-GCA to an extent that justifies the increased clinical effort. The relatively low sensitivity of 55% for US assessment of 22 arteries reported in the study by Aschwanden et al is probably explained by the fact that one-third of patients had extracranial LV-GCA and that the American College of Rheumatology (ACR) criteria were applied as the reference standard. The ACR criteria mainly capture patients with cranial GCA.<sup>29</sup>

In TAK, both studies on MRA and CTA revealed excellent sensitivities and specificities using conventional angiography as the reference standard. These studies, however, were small, included (partially) the same patients and there was a long interval between MRA/CTA and angiography.<sup>55 56</sup> Future studies on the diagnostic performance of imaging techniques in TAK are thus warranted, and there is a need for a novel reference standard, given that conventional angiography is highly invasive.

Current evidence on the role for imaging modalities for outcome prediction, as well as for monitoring disease activity and damage in LVV is limited. Although a response of vessel wall alterations to GC treatment was detected in both, cranial and extracranial LV-GCA and TAK.<sup>17</sup> 20 22 25 28 29 43-45 48-51 57 58 neither imaging findings at baseline nor during follow-up were clearly associated with a disease relapse or any other outcome. Besides, monitoring studies were mainly descriptive and without clear inferences, thus precluding drawing a clear conclusion from them that could be of further information for an SLR like ours. The decision to include these studies in the current SLR was solely based on content knowledge, while from a methodological point of view, this decision is obviously arguable. Now, 15 studies on monitoring are included in this SLR, as we were inclusive, and facing a scarcity of studies, tried to retrieve from the literature any information on the value of imaging for monitoring LVV. However, we could have also been somewhat more restrictive by only including studies that analysed any association between the imaging for monitoring and other outcomes (eg, relapse); if this was the case, no eligible study would have been found in the literature. The development of standard tools for monitoring disease activity and damage in LVV is urgently needed and might facilitate further research on the evaluation of the role of imaging for disease monitoring and outcome prediction.

Studies on minimal technical requirements, settings and operational procedures for the evaluation of patients with cranial and extracranial LV-GCA are also scarce. The quality of imaging devices is obviously a critical issue, because poor equipment may easily lead to misclassification of patients<sup>67</sup> and because heterogeneity in the quality of imaging devices renders comparison between studies difficult. To avoid this type of bias in our meta-analysis, we performed a sensitivity analysis focusing on studies using high-quality US machines only which resulted, as expected, in a higher sensitivity as compared with the main analysis (87% vs 77%), thus confirming the important role of using high-quality imaging devices.

In summary, this SLR confirms the good performance of US and MRI of the superficial temporal arteries for diagnosis of cranial GCA. More data on imaging techniques in LV-GCA and TAK are needed, as well as on the role of imaging for outcome prediction, monitoring and technical aspects of LVV, as current studies on these aspects are not conclusive. Based on the results of this SLR, EULAR recommendations for the use of imaging modalities in LVV in daily clinical practice have been developed.

#### Author affiliations

<sup>1</sup>Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria

<sup>2</sup>Rheumatology Service, South Tyrolean Health Trust, Hospital of Bruneck, Bruneck, Italy

<sup>3</sup>Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria

<sup>4</sup>Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

<sup>5</sup>NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal

<sup>6</sup>Center for Behavioral Cardiovascular Health, Columbia University Medical Center, New York City, New York, USA

<sup>7</sup>Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany

**Contributors** Study concept and design: ChristinD, ChristiaD, SR and WAS; data collection: ChristinD and ChristiaD; statistical analysis and data interpretation: AS, ChristinD, ChristiaD, SR and WAS; ChristinD prepared the first version of the manuscript. All authors revised the manuscript critically for important intellectual content and gave final approval of the version to be published.

Funding Funding was provided by the European League Against Rheumatism.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

#### REFERENCES

- Salvarani C, Pipitone N, Versari A, et al. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 2012;8:509–21.
- Direskeneli H. Clinical assessment in Takayasu's arteritis: major challenges and controversies. *Clin Exp Rheumatol* 2017;35(Suppl 103):189–93.
- Hall S, Persellin S, Lie JT, et al. The therapeutic impact of temporal artery biopsy. Lancet 1983;2:1217–20.

- Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318–23.
- Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–8.
- Luqmani R, Lee E, Singh S, *et al.* The role of ultrasound compared to biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. *Health Technol Assess* 2016;20:1–238.
- Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. *Arthritis Rheum* 1999;42:311–7.
- Schmidt WA, Seifert A, Gromnica-Ihle E, et al. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. *Rheumatology* 2008;47:96–101.
- 9. Arend WP, Michel BA, Bloch DA, *et al.* The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum* 1990;33:1129–34.
- Schmidt WA. Role of ultrasound in the understanding and management of vasculitis. *Ther Adv Musculoskelet Dis* 2014;6:39–47.
- Cinar I, Wang H, Stone JR. Clinically isolated aortitis: pitfalls, progress, and possibilities. *Cardiovasc Pathol* 2017;29:23–32.
- Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018. doi: 10.1136/annrheumdis-2017- 212649. [Epub ahead of print 22 Jan 2018].
- Sackett DL, Richardson WS, Rosenberg W, et al; Evidence Based Medicine-How to Practice and Teach EBM. London: Churchill Livingstone, 1997.
- Whiting PF, Rutjes AWS, Westwood ME, et al. Research and Reporting Methods Accuracy Studies. Ann Intern Med 2011;155:529–36.
- Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. *Ann Intern Med* 2006;144:427–37.
- Takwoingi Y, Guo B, Riley RD, *et al.* Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data. *Stat Methods Med Res* 2017;26.
- Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997;337:1336–42.
- LeSar CJ, Meier GH, DeMasi RJ, *et al.* The utility of color duplex ultrasonography in the diagnosis of temporal arteritis. *J Vasc Surg* 2002;36:1154–60.
- Nesher G, Shemesh D, Mates M, *et al*. The predictive value of the halo sign in color Doppler ultrasonography of the temporal arteries for diagnosing giant cell arteritis. *J Rheumatol* 2002;29:1224–6.
- Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med 2002;137:232–8.
- 21. Murgatroyd H, Nimmo M, Evans A, *et al*. The use of ultrasound as an aid in the diagnosis of giant cell arteritis: a pilot study comparing histological features with ultrasound findings. *Eye* 2003;17:415–9.
- Pfadenhauer K, Weber H. Duplex sonography of the temporal and occipital artery in the diagnosis of temporal arteritis. A prospective study. *J Rheumatol* 2003;30:2177–81.
- Reinhard M, Schmidt D, Hetzel A. Color-coded sonography in suspected temporal arteritis-experiences after 83 cases. *Rheumatol Int* 2004;24:340–6.
- Romera-Villegas A, Vila-Coll R, Poca-Dias V, et al. The role of color duplex sonography in the diagnosis of giant cell arteritis. *J Ultrasound Med* 2004;23:1493–8.
- 25. Karahaliou M, Vaiopoulos G, Papaspyrou S, *et al.* Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. *Arthritis Res Ther* 2006;8:R116.
- Pfadenhauer K, Behr C. The contribution of ultrasound of the craniocervical arteries to the diagnosis of giant cell arteritis. *Clin Ophthalmol* 2007;1:461–70.
- Zaragozá García JM, Plaza Martínez A, Briones Estébanez JL, et al. [Value of the Doppler-ultrasonography for the diagnosis of temporal arteritis]. *Med Clin* 2007;129:451–3.
- Habib HM, Essa AA, Hassan AA. Color duplex ultrasonography of temporal arteries: role in diagnosis and follow-up of suspected cases of temporal arteritis. *Clin Rheumatol* 2012;31:231–7.
- Aschwanden M, Kesten F, Stern M, *et al.* Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. *Ann Rheum Dis* 2010;69:1356–9.

6

## <u>6</u>

### Imaging

- Aschwanden M, Daikeler T, Kesten F, et al. Temporal artery compression sign – a novel ultrasound finding for the diagnosis of giant cell arteritis. *Ultraschall Med* 2013;34:47–50.
- Diamantopoulos AP, Haugeberg G, Hetland H, et al. Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res 2014;66:113–9.
- Aschwanden M, Imfeld S, Staub D, *et al.* The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. *Clin Exp Rheumatol* 2015;33(2 Suppl 89):S113–5.
- Bley TA, Weiben O, Uhl M, *et al.* Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. *Arthritis Rheum* 2005;52:2470–7.
- Bley TA, Uhl M, Carew J, et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol 2007;28:1722–7.
- Geiger J, Bley T, Uhl M, et al. Diagnostic value of T2-weighted imaging for the detection of superficial cranial artery inflammation in giant cell arteritis. J Magn Reson Imaging 2010;31:470–4.
- Veldhoen S, Klink T, Geiger J, et al. MRI displays involvement of the temporalis muscle and the deep temporal artery in patients with giant cell arteritis. *Eur Radiol* 2014;24:2971–9.
- Franke P, Markl M, Heinzelmann S, et al. Evaluation of a 32-channel versus a 12-channel head coil for high-resolution post-contrast MRI in giant cell arteritis (GCA) at 3T. Eur J Radiol 2014;83:1875–80.
- Klink T, Geiger J, Both M, et al. Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. *Radiology* 2014;273:844–52.
- Siemonsen S, Brekenfeld C, Holst B, et al. 3T MRI reveals extra- and intracranial involvement in giant cell arteritis. AJNR Am J Neuroradiol 2015;36:91–7.
- Rhéaume M, Rebello R, Pagnoux C, et al. High-Resolution Magnetic Resonance Imaging of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Cohort Study. Arthritis Rheumatol 2017;69:161–8.
- Blockmans D, Stroobants S, Maes A, et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000;108:246–9.
- Lariviere D, Benali K, Coustet B, et al. Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis: A real-life prospective study. *Medicine* 2016;95:e4146.
- Schmidt WA, Moll A, Seifert A, et al. Prognosis of large-vessel giant cell arteritis. *Rheumatology* 2008;47:1406–8.
- De Miguel E, Roxo A, Castillo C, *et al.* The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arteritis. *Clin Exp Rheumatol* 2012;30(1 Suppl 70):S34–8.
- Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006;55:131–7.
- Blockmans D, Coudyzer W, Vanderschueren S, et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. *Rheumatology* 2008;47:1179–84.
- 47. García-Martínez A, Arguis P, Prieto-González S, *et al.* Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). *Ann Rheum Dis* 2014;73:1826–32.
- Schmidt WA, Natusch A, Möller DE, et al. Involvement of peripheral arteries in giant cell arteritis: a color Doppler sonography study. *Clin Exp Rheumatol* 2002;20:309–18.

- Pérez López J, Solans Laqué R, Bosch Gil JA, et al. Colour-duplex ultrasonography of the temporal and ophthalmic arteries in the diagnosis and follow-up of giant cell arteritis. *Clin Exp Rheumatol* 2009;27(1 Suppl 52):S77–82.
- Both M, Ahmadi-Simab K, Reuter M, et al. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. *Ann Rheum Dis* 2008;67:1030–3.
- Prieto-González S, García-Martínez A, Tavera-Bahillo I, et al. Effect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. A prospective, longitudinal study. *Medicine* 2015;94:e486.
- Hautzel H, Sander O, Heinzel A, et al. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J Nucl Med 2008;49:1107–13.
- Martínez-Rodríguez I, del Castillo-Matos R, Quirce R, et al. Comparison of early (60 min) and delayed (180 min) acquisition of 18F-FDG PET/CT in large vessel vasculitis. *Rev Esp Med Nucl Imagen Mol* 2013;32:222–6.
- Martínez-Rodríguez I, Martínez-Amador N, Banzo I, et al. Assessment of aortitis by semiquantitative analysis of 180-min 18F-FDG PET/CT acquisition images. *Eur J Nucl Med Mol Imaging* 2014;41:2319–24.
- Yamada I, Nakagawa T, Himeno Y, *et al.* Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. *J Magn Reson Imaging* 2000;11:481–7.
   Yamada I, Nakagawa T, Himeno Y, *et al.* Takayasu arteritis:
- Yamada İ, Nakagawa T, Himeno Y, *et al.* Takayasu arteritis: evaluation of the thoracic aorta with CT angiography. *Radiology* 1998;209:103–9.
- 57. Fan W, Zhu J, Li J, *et al.* Ultrasound morphological changes in the carotid wall of Takayasu's arteritis: monitor of disease progression. *Int Angiol* 2016;35:586–92.
- Sun Y, Ma L, Ji Z, et al. Value of whole-body contrast-enhanced magnetic resonance angiography with vessel wall imaging in quantitative assessment of disease activity and follow-up examination in Takayasu's arteritis. *Clin Rheumatol* 2016;35:685–93.
- Karassa FB, Matsagas MI, Schmidt WA, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005;142:359–69.
- Ball EL, Walsh SR, Tang TY, et al. Role of ultrasonography in the diagnosis of temporal arteritis. Br J Surg 2010;97:1765–71.
- Arida A, Kyprianou M, Kanakis M, et al. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. *BMC Musculoskelet Disord* 2010;11:44.
- Buttgereit F, Dejaco C, Matteson EL, et al. Polymyalgia rheumatica and giant cell arteritis. JAMA 2016;315:2442–58.
- Hauenstein C, Reinhard M, Geiger J, et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. *Rheumatology* 2012;51:1999–2003.
- 64. Bley TA, Reinhard M, Hauenstein C, *et al.* Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. *Arthritis Rheum* 2008;58:2574–8.
- Czihal M, Zanker S, Rademacher A, et al. Sonographic and clinical pattern of extracranial and cranial giant cell arteritis. Scand J Rheumatol 2012;41:231–6.
- Czihal M, Tatò F, Rademacher A, et al. Involvement of the femoropopliteal arteries in giant cell arteritis: clinical and color duplex sonography. J Rheumatol 2012;39:314–21.
- Puppo C, Massollo M, Paparo F, et al. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. *Biomed Res Int* 2014;2014:1–11.